STOCK TITAN

Canton Strategic Q3 net loss widens to $35.1M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Canton Strategic Holdings, Inc. (CNTN) reported a net loss of $35,078,297 for the quarter ended September 30, 2026, compared with $2,101,838 a year earlier. Revenue was $3,051,232, comprising $1,503,238 in network validation and $1,547,994 in other revenue; the quarter also included $54,648,199 of unrealized losses on digital asset holdings. For the first nine months, revenue was $4,547,091 and net loss was $101,676,320, compared with a net loss of $6,498,695 in 2025.

At September 30, 2026, CNTN held 3,833,830,293 Canton Coins with a fair value of $482,149,407 and had $26,917,436 in cash and cash equivalents. It used $12,374,738 in operating cash over nine months. CNTN completed the sale of Gravitas on July 17, 2026, retaining certain bispecific antibody development assets; the related unsecured note had a $3,606,997 amortized cost basis at quarter-end, bears 15% annual interest, and matures July 17, 2029. The sale agreement also provides for cash milestone payments of up to $3,000,000 in aggregate upon specified clinical development and regulatory approval milestones.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • None.

Negative

  • Major pointNine-month net loss was $101,676,320, versus $6,498,695 in 2025.
  • Moderate pointNine-month operating cash use was $12,374,738, versus $5,686,700 in 2025.
  • Minor pointQuarterly net loss was $35,078,297, versus $2,101,838 a year earlier.

Filing Explained

At September 30, 2026, CNTN reported 114,281,286 pre-funded warrants against 81,107,017 common shares outstanding.

At September 30, 2026, Canton Strategic Holdings reported 114,281,286 cryptocurrency pre-funded warrants, 17,000,000 January offering pre-funded warrants, and 6,351,021 cash pre-funded warrants outstanding, rather than issued as common shares. If exercised, these warrants would add common shares and reduce existing holders’ percentage ownership, absent offsetting changes.

The cryptocurrency warrants had a $0 exercise price and the January offering warrants a $0.0001 exercise price; their stated offering prices were $3.075 and $2.9199, respectively. A pre-funded warrant converts into shares when exercised.

During the nine months ended September 30, 2026, the company sold 9,483,463 shares through its at-the-market offerings and issued 30,823,808 shares upon cashless exercise of cryptocurrency pre-funded warrants. It reported 81,638,745 common shares outstanding on November 13, 2026.

Quarterly revenue $3,051,232 Three months ended September 30, 2026; $0 in 2025.
Quarterly net loss $35,078,297 Three months ended September 30, 2026; compared with $2,101,838 in 2025.
Unrealized loss on digital asset holdings $54,648,199 Three months ended September 30, 2026.
Nine-month net loss $101,676,320 Nine months ended September 30, 2026; compared with $6,498,695 in 2025.
Cash and cash equivalents $26,917,436 September 30, 2026.
Digital assets fair value $482,149,407 September 30, 2026.
Net cash used in operating activities $12,374,738 Nine months ended September 30, 2026; compared with $5,686,700 in 2025.
Gravitas Note amortized cost basis $3,606,997 September 30, 2026; includes accrued payment-in-kind interest.
burn-and-mint equilibrium model technical
"CC is issued under a burn-and-mint equilibrium model"
Super Validator technical
"operating a Validator and Super Validator on the Canton Network"
A super validator is an entity or operator in a proof‑of‑stake cryptocurrency network that has been selected or earned the right to check and confirm transactions and create new blocks more often than ordinary validators. Think of it like a trusted traffic controller for a digital ledger: its reliability and influence affect how quickly and securely the network runs, how rewards are distributed, and how decision‑making power is concentrated—factors investors watch for risk, return and governance implications.
locking-as-a-service technical
"The Company provides locking-as-a-service (LAAS)"
A paid, cloud-delivered service that manages and enforces locks on assets, accounts, devices, or digital keys on behalf of customers. Think of it like hiring a building manager who controls who can open which doors and when—only applied to software keys, access controls, token vesting, or physical locks via connected hardware. Investors care because it turns a technical security function into a recurring revenue business and can affect a company’s operational risk and compliance profile.
payment-in-kind interest financial
"including accrued payment-in-kind interest of $106,997"
Payment-in-kind interest is interest that a borrower pays not with cash but by increasing the loan balance or issuing additional securities, like receiving more IOUs instead of money. For investors this matters because it reduces immediate cash receipts, can dilute ownership or increase a company’s debt load over time, and signals how comfortably a borrower can meet cash obligations — all factors that affect valuation and credit risk.
Level 1 inputs financial
"The fair value of CC uses Level 1 inputs"
ASC 606 by analogy financial
"applies the recognition and measurement principles of ASC 606 by analogy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did CNTN report a net loss in Q3 2026?

CNTN recorded a net loss of $35,078,297 for the three months ended September 30, 2026, including $54,648,199 in unrealized losses on digital asset holdings.

What terms did CNTN disclose for the Gravitas note?

At September 30, 2026, the unsecured Gravitas Note had an amortized cost basis of $3,606,997, including $106,997 of payment-in-kind interest. It bears interest at 15% per annum and matures July 17, 2029; the sale agreement also provides for up to $3,000,000 in aggregate cash milestone payments upon specified clinical development and regulatory approval milestones.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0001861657 http://fasb.org/srt/2026#CryptoAssetOtherMember http://fasb.org/srt/2026#CryptoAssetOtherMember http://fasb.org/srt/2026#CryptoAssetOtherMember 0001861657 2026-01-01 2026-09-30 0001861657 2026-11-13 0001861657 2026-09-30 0001861657 2025-12-31 0001861657 2026-07-01 2026-09-30 0001861657 2025-07-01 2025-09-30 0001861657 2025-01-01 2025-09-30 0001861657 CNTN:NetworkValidationRevenueMember 2026-07-01 2026-09-30 0001861657 CNTN:NetworkValidationRevenueMember 2025-07-01 2025-09-30 0001861657 CNTN:NetworkValidationRevenueMember 2026-01-01 2026-09-30 0001861657 CNTN:NetworkValidationRevenueMember 2025-01-01 2025-09-30 0001861657 CNTN:OtherRevenueMember 2026-07-01 2026-09-30 0001861657 CNTN:OtherRevenueMember 2025-07-01 2025-09-30 0001861657 CNTN:OtherRevenueMember 2026-01-01 2026-09-30 0001861657 CNTN:OtherRevenueMember 2025-01-01 2025-09-30 0001861657 us-gaap:CommonStockMember 2025-06-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001861657 us-gaap:RetainedEarningsMember 2025-06-30 0001861657 us-gaap:TreasuryStockCommonMember 2025-06-30 0001861657 2025-06-30 0001861657 us-gaap:CommonStockMember 2024-12-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001861657 us-gaap:RetainedEarningsMember 2024-12-31 0001861657 us-gaap:TreasuryStockCommonMember 2024-12-31 0001861657 2024-12-31 0001861657 us-gaap:CommonStockMember 2026-06-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001861657 us-gaap:RetainedEarningsMember 2026-06-30 0001861657 us-gaap:TreasuryStockCommonMember 2026-06-30 0001861657 2026-06-30 0001861657 us-gaap:CommonStockMember 2025-12-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001861657 us-gaap:RetainedEarningsMember 2025-12-31 0001861657 us-gaap:TreasuryStockCommonMember 2025-12-31 0001861657 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001861657 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001861657 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001861657 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001861657 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001861657 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-30 0001861657 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001861657 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001861657 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0001861657 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001861657 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001861657 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-09-30 0001861657 us-gaap:CommonStockMember 2025-09-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001861657 us-gaap:RetainedEarningsMember 2025-09-30 0001861657 us-gaap:TreasuryStockCommonMember 2025-09-30 0001861657 2025-09-30 0001861657 us-gaap:CommonStockMember 2026-09-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001861657 us-gaap:RetainedEarningsMember 2026-09-30 0001861657 us-gaap:TreasuryStockCommonMember 2026-09-30 0001861657 us-gaap:IPOMember 2025-07-01 2025-09-30 0001861657 us-gaap:PrivatePlacementMember 2025-07-01 2025-09-30 0001861657 us-gaap:IPOMember 2025-01-01 2025-09-30 0001861657 us-gaap:PrivatePlacementMember 2025-01-01 2025-09-30 0001861657 CNTN:InterestLoanTypeArrangementMember 2026-07-01 2026-09-30 0001861657 CNTN:InterestLoanTypeArrangementMember 2026-01-01 2026-09-30 0001861657 CNTN:RevenueShareArrangementsMember 2026-07-01 2026-09-30 0001861657 CNTN:RevenueShareArrangementsMember 2026-01-01 2026-09-30 0001861657 CNTN:EquityCompensationArrangementMember 2026-07-01 2026-09-30 0001861657 CNTN:EquityCompensationArrangementMember 2026-01-01 2026-09-30 0001861657 CNTN:CryptoCurrencyContractMember 2026-07-01 2026-09-30 0001861657 CNTN:CryptoCurrencyContractMember 2026-01-01 2026-09-30 0001861657 CNTN:PurchaseAgreementMember 2026-01-01 2026-09-30 0001861657 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001861657 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001861657 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001861657 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001861657 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001861657 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001861657 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0001861657 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001861657 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001861657 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001861657 CNTN:CCReceiptMember 2026-01-01 2026-09-30 0001861657 CNTN:CashSecuritiesPurchaseAgreementsMember 2025-11-03 2025-11-03 0001861657 CNTN:CashSecuritiesPurchaseAgreementsMember CNTN:PrefundedWarrantsMember 2025-11-03 0001861657 CNTN:CashSecuritiesPurchaseAgreementsMember 2025-11-03 0001861657 CNTN:CryptocurrencyOfferingMember CNTN:PrefundedWarrantsMember 2025-11-03 0001861657 CNTN:CryptocurrencyOfferingMember CNTN:PrefundedWarrantsMember 2025-11-03 2025-11-03 0001861657 CNTN:CashOfferingAndCryptocurrencyOfferingMember 2025-11-03 2025-11-03 0001861657 CNTN:CashOfferingAndCryptocurrencyOfferingMember 2025-11-03 2026-11-03 0001861657 CNTN:CashSecuritiesPurchaseAgreementsAndCrytocurrencySecuritiesPurchaseAgreementsMember CNTN:StrategicAdvisorWarrantsMember 2025-11-03 0001861657 CNTN:TwoThousandTwentyFiveATMAgreementMember srt:MaximumMember CNTN:AtMarketEquityOfferingsMember 2025-11-06 2025-11-06 0001861657 CNTN:TwoThousandTwentyFiveATMAgreementMember 2025-01-01 2025-12-31 0001861657 us-gaap:CommonStockMember 2026-01-21 2026-01-21 0001861657 us-gaap:CommonStockMember 2026-01-21 0001861657 CNTN:PrefundedWarrantsMember 2026-01-21 0001861657 2026-01-21 0001861657 2026-01-21 2026-01-21 0001861657 CNTN:MarchTwoThousandTwentySixATMAgreementMember CNTN:AtMarketEquityOfferingsMember 2026-03-03 2026-03-03 0001861657 CNTN:MarchTwoThousandTwentySixATMAgreementMember CNTN:AtMarketEquityOfferingsMember 2026-07-01 2026-09-30 0001861657 CNTN:MarchTwoThousandTwentySixATMAgreementMember CNTN:AtMarketEquityOfferingsMember 2026-01-01 2026-09-30 0001861657 CNTN:TwoThousandTwentyFiveATMAgreementMember 2026-01-01 2026-09-30 0001861657 CNTN:MarchTwoThousandTwentySixATMAgreementMember 2026-01-01 2026-09-30 0001861657 CNTN:JanuaryTwoThousandTwentySixOfferingMember 2026-01-01 2026-09-30 0001861657 CNTN:TwoThousandSeventeenStockIncentivePlanMember 2026-09-30 0001861657 CNTN:TwoThousandSeventeenStockIncentivePlanMember 2026-01-01 2026-09-30 0001861657 CNTN:TwoThousandSeventeenStockIncentivePlanMember 2025-12-31 0001861657 CNTN:TwoThousandNineteenStockIncentivePlanMember 2026-01-01 2026-09-30 0001861657 CNTN:TwoThousandNineteenStockIncentivePlanMember 2026-09-30 0001861657 CNTN:TwoThousandNineteenStockIncentivePlanMember 2025-12-31 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-01-01 2025-01-01 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-06-10 2025-06-10 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-10-09 2025-10-09 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-10-09 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-01-29 2026-01-29 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-01-30 2026-01-30 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-01-01 2026-09-30 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-01-01 2025-12-31 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-01-01 2025-09-30 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-09-30 0001861657 CNTN:StrategicAdvisorWarrantsMember 2026-01-01 2026-09-30 0001861657 CNTN:StrategicAdvisorWarrantsMember 2026-09-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2026-06-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2026-07-01 2026-09-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2025-07-01 2025-09-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember CNTN:JanuaryTwoThousandTwentyFiveMember 2026-01-01 2026-09-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember CNTN:FebruaryTwoThousandTwentySixMember 2026-01-01 2026-09-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0001861657 2025-01-01 2025-12-31 0001861657 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2025-01-01 2025-09-30 0001861657 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2025-01-01 2025-09-30 0001861657 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001861657 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2025-09-30 0001861657 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2025-09-30 0001861657 CNTN:WarrantsOneMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsOneMember 2026-09-30 0001861657 CNTN:WarrantsTwoMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsTwoMember 2026-09-30 0001861657 CNTN:WarrantsThreeMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsThreeMember 2026-09-30 0001861657 CNTN:WarrantsFourMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsFourMember 2026-09-30 0001861657 CNTN:WarrantsFiveMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsFiveMember 2026-09-30 0001861657 CNTN:WarrantsSixMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsSixMember 2026-09-30 0001861657 CNTN:WarrantsSevenMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsSevenMember 2026-09-30 0001861657 CNTN:WarrantsEightMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsEightMember 2026-09-30 0001861657 CNTN:WarrantsNineMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsNineMember 2026-09-30 0001861657 CNTN:WarrantsTenMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsTenMember 2026-09-30 0001861657 CNTN:WarrantsElevenMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsElevenMember 2026-09-30 0001861657 CNTN:WarrantsTwelveMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsTwelveMember 2026-09-30 0001861657 CNTN:WarrantsThirteenMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsThirteenMember 2026-09-30 0001861657 CNTN:WarrantsFourteenMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsFourteenMember 2026-09-30 0001861657 CNTN:WarrantsFifteenMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsFifteenMember 2026-09-30 0001861657 CNTN:WarrantsSixteenMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsSixteenMember 2026-09-30 0001861657 CNTN:WarrantsSeventeenMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsSeventeenMember 2026-09-30 0001861657 CNTN:WarrantsEighteenMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsEighteenMember 2026-09-30 0001861657 CNTN:WarrantsNineteenMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsNineteenMember 2026-09-30 0001861657 CNTN:WarrantsTwentyMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsTwentyMember 2026-09-30 0001861657 CNTN:WarrantsTwentyOneMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsTwentyOneMember 2026-09-30 0001861657 CNTN:WarrantsTwentyTwoMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsTwentyTwoMember 2026-09-30 0001861657 CNTN:WarrantsTwentyThreeMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsTwentyThreeMember 2026-09-30 0001861657 CNTN:WarrantsTwentyFourMember 2026-01-01 2026-09-30 0001861657 CNTN:WarrantsTwentyFourMember 2026-09-30 0001861657 us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001861657 us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001861657 us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001861657 us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001861657 us-gaap:GeneralAndAdministrativeExpense 2026-07-01 2026-09-30 0001861657 us-gaap:GeneralAndAdministrativeExpense 2025-07-01 2025-09-30 0001861657 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001861657 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001861657 us-gaap:ShareBasedCompensation 2026-07-01 2026-09-30 0001861657 us-gaap:ShareBasedCompensation 2025-07-01 2025-09-30 0001861657 us-gaap:ShareBasedCompensation 2026-01-01 2026-09-30 0001861657 us-gaap:ShareBasedCompensation 2025-01-01 2025-09-30 0001861657 2023-01-01 2023-01-31 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2023-07-27 2023-07-27 0001861657 CNTN:ABSIMember 2023-07-04 2023-07-05 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember srt:MaximumMember 2023-07-04 2023-07-05 0001861657 2024-03-11 2024-03-11 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2025-07-01 2025-09-30 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2025-01-01 2025-09-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2023-11-03 2023-11-03 0001861657 srt:MaximumMember 2023-11-03 2023-11-03 0001861657 CNTN:AviorPatentLicenseAgreementMember 2026-07-01 2026-09-30 0001861657 CNTN:AviorPatentLicenseAgreementMember 2026-01-01 2026-09-30 0001861657 CNTN:AviorPatentLicenseAgreementMember 2025-07-01 2025-09-30 0001861657 CNTN:AviorPatentLicenseAgreementMember 2025-01-01 2025-09-30 0001861657 CNTN:EnkefalosLicenseAgreementMember 2024-06-17 2024-06-17 0001861657 CNTN:EnkefalosLicenseAgreementMember 2025-01-01 2025-09-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2024-09-11 2024-09-11 0001861657 CNTN:IntractPatentLicenseAgreementMember 2025-01-01 2025-09-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2026-07-01 2026-09-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2026-01-01 2026-09-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2025-07-01 2025-09-30 0001861657 us-gaap:RelatedPartyMember CNTN:PresidentStreetGlobalMember 2025-12-31 0001861657 us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001861657 us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001861657 CNTN:GravitasMember 2026-07-01 2026-09-30 0001861657 CNTN:GravitasMember 2026-01-01 2026-09-30 0001861657 CNTN:GravitasNoteMember 2026-07-01 2026-09-30 0001861657 CNTN:GravitasNoteMember 2026-01-01 2026-09-30 0001861657 CNTN:GravitasNoteMember 2026-09-30 0001861657 2026-07-17 2026-07-17 0001861657 2026-07-17 0001861657 CNTN:DigitalAssetTreasuryMember 2026-09-30 0001861657 CNTN:DigitalAssetTreasuryMember 2025-12-31 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2026-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2025-12-31 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2026-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2025-12-31 0001861657 CNTN:DigitalAssetTreasuryMember 2026-07-01 2026-09-30 0001861657 CNTN:DigitalAssetTreasuryMember 2025-07-01 2025-09-30 0001861657 CNTN:DigitalAssetTreasuryMember 2026-01-01 2026-09-30 0001861657 CNTN:DigitalAssetTreasuryMember 2025-01-01 2025-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember 2026-07-01 2026-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember 2025-07-01 2025-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember 2026-01-01 2026-09-30 0001861657 CNTN:ClinicalStageBioTechnologyMember 2025-01-01 2025-09-30 0001861657 CNTN:GravitasNoteMember 2026-09-30 0001861657 CNTN:GravitasNoteMember 2026-01-01 2026-09-30 0001861657 CNTN:MileStonePaymentsMember 2026-01-01 2026-09-30 0001861657 CNTN:MileStonePaymentsMember srt:MaximumMember 2026-01-01 2026-09-30 0001861657 CNTN:MileStonePaymentsMember CNTN:IntractPharmaLimitedMember 2026-01-01 2026-09-30 0001861657 CNTN:GainOnSaleMember 2026-07-01 2026-09-30 0001861657 CNTN:GainOnSaleMember 2026-01-01 2026-09-30 0001861657 CNTN:GainOnSaleMember 2026-09-30 0001861657 us-gaap:SubsequentEventMember 2026-10-07 2026-10-07 0001861657 us-gaap:SubsequentEventMember 2026-10-08 2026-10-08 0001861657 us-gaap:SubsequentEventMember 2026-10-01 2026-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CNTN:Integer CNTN:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to _________

 

Commission file number 001-41210

 

CANTON STRATEGIC HOLDINGS, INC.

(Exact name of registrant as specified in charter)

 

Delaware   84-2642541
(State or jurisdiction of
Incorporation or organization)
  I.R.S. Employer
Identification No.

 

1460 Broadway, New York, NY   10036
(Address of principal executive offices)   (Zip code)

 

(212) 210-6006

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.0001 par value   CNTN   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Number of shares of common stock outstanding as of November 13, 2026 was 81,638,745.

 

 

 

 

 

 

TABLE OF CONTENTS

 

  Page No.
PART I – FINANCIAL INFORMATION  
     
ITEM 1. FINANCIAL STATEMENTS  
     
  Condensed Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 F-1
     
  Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) F-2
     
  Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) F-3
     
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 (Unaudited) F-4
     
  Notes to Condensed Consolidated Financial Statements F-5
     
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 4
     
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 15
     
ITEM 4. CONTROLS AND PROCEDURES 15
     
PART II – OTHER INFORMATION  
     
ITEM 1. LEGAL PROCEEDINGS 16
     
ITEM 1A. RISK FACTORS 16
     
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 16
     
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 16
     
ITEM 4. MINE SAFETY DISCLOSURES 16
     
ITEM 5. OTHER INFORMATION 16
     
ITEM 6. EXHIBITS 17
     
  SIGNATURES 18

 

2

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

 

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

 

  ● our projected financial position and estimated cash burn rate;
  ● our estimates regarding expenses, future revenues and capital requirements;
  ● the adoption of a digital asset treasury;
  ● our ability to continue as a going concern;
  ● fluctuations in the market price of Canton Coin;
  ● our future growth and operational progress;
  ● our ability to become profitable;
  ● our future financing arrangements;
  ●

our future network validation rewards, revenues from locking as a service, and option contract operations;

  ●

market acceptance of our products and services;

  ● our future expenses and cash flow;
  ● our future stock price;
  ● our ability to build commercial infrastructure;
  ● failure to realize the anticipated benefits of the digital asset treasury strategy;
  ● changes in business, market, financial, political and regulatory conditions;
  ● risks relating to our operations and business, including the highly volatile nature of the price of Canton Coin and other cryptocurrencies;
  ● the risk that the price of our common stock may be highly correlated to the price of the digital assets that we hold;
  ● our ability to operate as a Super Validator and run additional Validators on the Canton Network;
  ● our dependence on third parties to carry out our operations;
  ● our ability to comply with applicable laws;
  ● the results of market research conducted by us or others;
  ● our ability to protect our intellectual property rights;
  ● our ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel; and
  ● general business and economic conditions.

 

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

 

This Quarterly Report on Form 10-Q may include market data and certain industry data and forecasts, which we may obtain from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications, articles and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third-party sources.

 

3

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

CANTON STRATEGIC HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   September 30,   December 31, 
   2026   2025 
         
ASSETS          
           
Current assets          
Cash and cash equivalents  $26,917,436   $12,007,148 
Prepaid expenses and other current assets   1,259,393    197,383 

Note receivable (related party)

   

1,125,000

      
Current assets held for sale   -    5,181,535 
           
Total current assets   29,301,829    17,386,066 
           
Digital assets   482,149,407    501,760,369 
Note receivable (related party)   2,481,997    - 
           
Total non-current assets   

484,631,404

    501,760,369 
           
Total assets  $513,933,233   $519,146,435 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities          
Accounts payable  $52,662   $521,201 
Accrued expenses   1,485,463    506,460 
Current liabilities held for sale   -    2,258,703 
           
Total current liabilities   1,538,125    3,286,364 
           
Deferred tax liability   91,714,327    117,934,191 
           
Total liabilities   93,252,452    121,220,555 
           
Commitments and contingencies (see Note 7)   -    - 
           
Stockholders’ equity          
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2026 and December 31, 2025   -    - 
Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of September 30, 2026 and December 31, 2025, 81,107,263 shares and 37,112,466 shares issued and 81,107,017 shares and 37,112,220 shares outstanding as of September 30, 2026 and December 31, 2025, respectively   8,110    3,711 
Additional paid-in capital   595,236,300    470,809,478 
Accumulated deficit   (174,493,664)   (72,817,344)
Treasury stock, at cost, 246 shares held in treasury as of September 30, 2026 and December 31, 2025, respectively   (69,965)   (69,965)
           
Total stockholders’ equity   420,680,781    397,925,880 
           
Total liabilities and stockholders’ equity  $513,933,233   $519,146,435 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

F-1

 

 

CANTON STRATEGIC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   2026   2025   2026   2025 
   For the Three Months Ended September 30,   For the Nine Months Ended September 30, 
   2026   2025   2026   2025 
                 
Revenue                    
Network validation revenue  $1,503,238   $-   $1,694,464   $- 
Other revenue   1,547,994    -    2,852,627    - 
                     
Total revenue  $3,051,232    -   $

4,547,091

    - 
                     
Operating expenses                    
Research and development   -    101,586    -    316,673 
General and administrative   2,710,641    1,815,775    40,629,835    5,073,330 
                     
Total operating expenses   2,710,641    1,917,361    40,629,835    5,390,003 
                     
Income (loss) from operations   340,591    (1,917,361)   (36,082,744)   (5,390,003)
                     
Other income (expense)                    
Interest expense   -    (9,648)   -    (24,280)
Interest income   376,820    1,388    1,006,846    16,992 
Unrealized loss from digital assets holdings   (54,648,199)   -    (93,397,453)   - 
                     
Total other expense, net   (54,271,379)   (8,260)   (92,390,607)   (7,288)
                     
Loss before income taxes   (53,930,788)   (1,925,621)   (128,473,351)   (5,397,291)
                     
Benefit for income taxes   (15,327,449)   -    (26,219,864)   - 
Net loss from continuing operations   (38,603,339)   (1,925,621)   (102,253,487)   (5,397,291)
Net income (loss) from discontinued operations   3,525,042    (176,217)   577,167    (1,101,404)
                     
Net loss  $(35,078,297)  $(2,101,838)  $(101,676,320)  $(6,498,695)
                     
Net loss per share:                    
Continuing operations – basic and diluted  $(0.18)  $(0.31)  $(0.48)  $(1.38)
Discontinued operations – basic and diluted  $0.02   $(0.03)  $-   $(0.28)
                     
Net loss per share – basic and diluted  $(0.16)  $(0.34)  $(0.47)  $(1.66)
                     
Weighted average number of common shares outstanding:                    
Basic and diluted   218,436,090    6,241,909    214,374,949    3,910,757 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

F-2

 

 

CANTON STRATEGIC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025 (UNAUDITED)

 

   Shares   Amount   Capital   Deficit   Shares   Amount   Total 
   Common Stock   Additional
Paid-in
   Accumulated   Treasury Stock     
   Shares   Amount   Capital   Deficit   Shares   Amount   Total 
                             
For the three months ended September 30, 2025:                                   
                                    
Balance, June 30, 2025   4,221,166   $422   $41,734,853   $(41,297,951)   246   $(69,965)  $367,359 
                                    
Registered direct public offering, net of issuance costs of $793,005   620,108    62    6,296,947    -    -    -    6,297,009 
                                    
Private investment in public equity offering, net of issuance costs of $202,214   641,190    64    1,065,219    -    -    -    1,065,283 
                                    
Cashless exercise of pre-funded warrants   1,458,553    146    (146)   -    -    -    - 
                                    
Cashless exercise of common warrants   266,570    27    (27)   -    -    -    - 
                                    
Net loss   -    -    -    (2,101,838)   -    -    (2,101,838)
                                    
Stock based compensation   -    -    527,014    -    -    -    527,014 
Balance, September 30, 2025   7,207,587   $721   $49,623,860   $(43,399,789)   246   $(69,965)  $6,154,827 
                                    
For the nine months ended September 30, 2025:                                   
                                    
Balance, December 31, 2024   1,973,999   $198   $38,278,503   $(36,901,094)   246   $(69,965)  $1,307,642 
                                    
Registered direct public offering, net of issuance costs of $793,005   620,108    62    6,296,947    -    -    -    6,297,009 
                                    
Private investment in public equity offering, net of issuance costs of $568,740   2,192,541    219    3,325,064    -    -    -    3,325,283 
                                    
At-the-market offering, net of issuance costs   163,359    16    219,531    -    -    -    219,547 
                                    
Cashless exercise of pre-funded warrants   1,949,710    195    (195)   -    -    -    - 
                                    
Cashless exercise of common warrants   266,570    27    (27)   -    -    -    - 
                                    
Stock issuance pursuant to bonus liability   -    -    200,212    -    -    -    200,212 
                                    
Restricted stock unit issuance pursuant to services agreement   35,000    3    (3)   -    -    -    - 
                                    
Issuance costs related to Form S-8 Options Registration Statement   -    -    (10,000)   -    -    -    (10,000)
                                    
Stock issuance pursuant to termination agreement   6,300    1    8,252    -    -    -    8,253 
                                    
Net loss   -    -    -    (6,498,695)   -    -    (6,498,695)
                                    
Stock based compensation   -    -    1,305,576    -    -    -    1,305,576 
Balance, September 30, 2025   7,207,587   $721   $49,623,860   $(43,399,789)   246   $(69,965)  $6,154,827 
                                    
For the three months ended September 30, 2026:                                   
                                    
Balance, June 30, 2026   77,273,206   $7,727   $594,380,217   $(139,415,367)   246   $(69,965)  $454,902,612 
                                    
At-the-market offerings, net of issuance costs   369,125    37    856,429    -    -    -    856,466 
                                    
Cashless exercise of pre-funded warrants   3,464,932    346    (346)   -    -    -    - 
                                    
Net loss   -    -    -    (35,078,297)   -    -    (35,078,297)
Balance, September 30, 2026   81,107,263   $8,110   $595,236,300   $(174,493,664)   246   $(69,965)  $420,680,781 
                                    
For the nine months ended September 30, 2026:                                   
                                    
Balance, December 31, 2025   37,112,466   $3,711   $470,809,478   $(72,817,344)   246   $(69,965)  $397,925,880 
                                    
Underwritten offering, net of issuance costs   1,800,000    180    52,698,348    -    -    -    52,698,528 
                                    
At-the-market offerings, net of issuance costs   9,483,463    948    40,050,328    -    -    -    40,051,276 
                                    
Cashless exercise of pre-funded warrants   30,823,808    3,082    (3,082)   -    -    -    - 
                                    
Exercise of common warrants   1,674,091    167    186,412    -    -    -    186,579 
                                    
Cashless exercise of common warrants   50,834    6    (6)   -    -    -    - 
                                    
Restricted stock unit issuance pursuant to services agreement   162,601    16    (16)   -    -    -    - 
                                    
Issuance costs   -    -    (834,775)   -    -    -    (834,775)
                                    
Net loss   -    -    -    (101,676,320)   -    -    (101,676,320)
                                    
Stock based compensation   -    -    32,329,613    -    -    -    32,329,613 
Balance, September 30, 2026   81,107,263   $8,110   $595,236,300   $(174,493,664)   246   $(69,965)  $420,680,781 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

F-3

 

 

CANTON STRATEGIC HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

 

         
   For the Nine Months Ended September 30, 
   2026   2025 
         
Cash flows from operating activities:          
           
Net loss  $(101,676,320)  $(6,498,695)
Net income (loss) from discontinued operations   577,167    (1,101,404)
Net loss from continuing operations   (102,253,487)   (5,397,291)
Adjustments to reconcile net loss to net cash used in operating activities:          
Non-cash revenue from network validation and services   (4,512,232)   - 
Unrealized loss from digital assets holdings and receivables   93,397,453    - 
Deferred tax benefit   (26,219,864)   - 
Payment-in-kind interest on note receivable   (106,997)   - 
Write-off of deferred offering costs   -    92,168 
Stock based compensation   32,329,613    856,035 
Stock issuance pursuant to termination agreement   -    8,253 
Increase in operating assets:          
Prepaid expenses and other current assets   (375,055)   (43,775)
Increase (decrease) in operating liabilities:          
Accounts payable   (585,005)   246,517 
Accrued expenses   406,913    (252,480)
Net cash used in operating activities – continuing operations   (7,918,661)   (4,490,573)
Net cash used in operating activities – discontinued operations   (4,456,077)   (1,196,127)
Net cash used in operating activities   (12,374,738)   (5,686,700)
           
Cash flows from investing activities:          
Purchase of digital assets   (69,842,182)   - 
Net cash used in investing activities   (69,842,182)   - 
           
Cash flows from financing activities:          
Proceeds from issuance of common stock upon registered direct public equity offerings   54,894,300    7,090,014 
Proceeds from issuance of common stock upon private investment in public equity offerings   -    3,725,003 
Proceeds from issuance of common stock upon at-the-market offerings   40,661,194    266,625 
Proceeds from exercise of common stock warrants   186,579    - 
Payment of deferred offering costs and other issuance costs   (3,640,465)   (1,224,971)
Proceeds from insurance premium financing liability   -    285,178 
Repayment of insurance premium financing liability   -    (250,802)
Repayments of note payable   -    (153,368)
Net cash provided by financing activities   92,101,608    9,737,679 
           
Net increase in cash   9,884,688    4,050,979 
           
Cash, beginning of period – including discontinued operations   17,032,748    3,559,361 
           
Cash, end of period – including discontinued operations  $26,917,436   $7,610,340 
Cash, end of period – discontinued operations  $-   $- 
Cash, end of period – continuing operations  $26,917,436   $7,610,340 
           
Supplemental disclosure of non-cash investing and financing activities:          
Note receivable received as consideration for the sale of Gravitas  $3,500,000   $- 
Placement agent warrants issued as issuance costs of private investment in public equity offerings  $-   $169,019 
Amortization of deferred offering cost from ATM offering   -    24,832 
Reduction of premium related to insurance premium financing   -    101,102 
Issuance of note payable for settlement of previously incurred professional fees   -    314,485 
Issuance of options to settle liability   -    200,212 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

F-4

 

 

CANTON STRATEGIC HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

Note 1 – Description of Business

 

Nature of Operations

 

Canton Strategic Holdings, Inc., formerly known as Tharimmune, Inc. (“Canton Strategic,” “Tharimmune,” or the “Company”) was incorporated on March 28, 2017, as a Delaware C-corporation. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including Gravitas Life Sciences, Inc. (“Gravitas”), formerly known as Hillstream Oncology, Inc., through its sale on July 17, 2026.

 

Digital Asset Treasury Strategy

 

On November 6, 2025, in connection with a private placement with certain accredited investors (see Note 4 to the consolidated financial statements), Canton Strategic Holdings, Inc. announced the launch of a digital asset treasury strategy, pursuant to which the Company became the first publicly traded company to leverage Canton Coin (“CC”) and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets.

 

Under the new treasury policy and strategy, the principal holding in our treasury reserve on the balance sheet will be allocated to digital assets, primarily CC by applying a public-market treasury model to an asset that is believed to be earlier in its lifecycle, structurally reflexive, and underexposed as compared to other digital assets. The planned approach involves acquiring CC directly through operation as a Super Validator and run additional Validators on the Canton Network as a mechanism to obtain additional CC.

 

On February 18, 2026, in conjunction with this strategy, the Company changed its name from Tharimmune, Inc. to Canton Strategic Holdings, Inc., pursuant to an amended and restated Certificate of Incorporation filed with the Delaware Secretary of State.

 

During the three months ended June 30, 2026, the Company adopted a plan to dispose of its clinical-stage biotechnology business in order to focus its resources on the Canton Network focused digital asset treasury strategy. On July 17, 2026, the Company completed the sale of all of the issued and outstanding membership interests of Gravitas (the “Gravitas Transaction”) and retained certain assets of Gravitas relating to bispecific antibodies development (the “Oncology Program”) through its wholly owned subsidiary, Tharimmune SPV1, LLC. See Note 10 for further information regarding the Gravitas Transaction and discontinued operations.

 

Note 2 – Summary of Significant Accounting Policies

 

Basis of Presentation

 

These interim unaudited condensed consolidated financial statements (the “Interim Statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”) and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements as certain information has been condensed or omitted. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, these Interim Statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year. These Interim Statements should be read in conjunction with the audited consolidated financial statements and notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC (“2025 Annual Report”).

 

F-5

 

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of Canton Strategic and its wholly-owned subsidiaries, including Gravitas through the closing of the Gravitas Transaction on July 17, 2026 (see Note 10). All significant intercompany balances and transactions have been eliminated in consolidation.

 

Discontinued Operations

 

During the three months ended June 30, 2026, management committed to a plan for the divestiture of the Company’s wholly owned subsidiary, Gravitas. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-20, management evaluated the held for sale criteria under ASC 360-10-45-9 and concluded that Gravitas should be reported as discontinued operations in the financial statements included herein.

 

The assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities held for sale in the Condensed Consolidated Balance Sheets as of December 31, 2025; following the July 17, 2026 closing of the Gravitas Transaction, no assets or liabilities held for sale remain as of September 30, 2026. The results of the discontinued operations, including the gain on sale of Gravitas, are aggregated and presented separately in the Condensed Consolidated Statements of Operations as net income (loss) from discontinued operations for the three and nine months ended September 30, 2026 and 2025. The cash flows of the discontinued operations are reflected as cash flows from discontinued operations within the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025.

 

Amounts presented in assets and liabilities held for sale, and discontinued operations have been derived from our condensed consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Gravitas business activities. See Note 10 for additional information on discontinued operations.

 

Revenue Recognition

 

The Company earns CC reward revenue through operating a Validator and Super Validator on the Canton Network. The Canton Network’s native token, CC, is issued under a burn-and-mint equilibrium model rather than a fixed block-reward schedule. New CC is minted approximately every ten minutes (a “round”) and allocated among three participant classes - Super Validators, Validators, and application providers - based on protocol-defined formulas. There is no identifiable counterparty that has contracted with the Company, negotiated terms, or agreed to pay consideration in exchange for a distinct good or service provided by the Company to that counterparty. As there is no customer or contract associated with the CC reward revenue, the Company applies the recognition and measurement principles of ASC 606 by analogy. The Company’s obligation is to provide validation/liveness services to the network for a given round. That obligation is satisfied - and the related reward is earned - at the completion of each round, when the Company has performed the requisite activity and the reward coupon becomes claimable/mintable. Rewards are received in CC, a non-cash asset. For purposes of applying ASC 606 by analogy, the Company considers its participation in each round to represent a separate arrangement and its validation and liveness activities for that round to represent a single performance obligation. No further performance obligations exist once a round’s reward is minted; there is no unsatisfied obligation requiring deferral of income into future periods. CC reward revenues are reported as Network validation revenue in the condensed consolidated statements of operations.

 

The Company provides locking-as-a-service (“LAAS”) to Canton Network Super Validators and Featured Applications, which are required under Canton Improvement Proposals (“CIP”) 105 and 116 to maintain a qualifying amount of CC identifiably locked. The Company locks its own CC on the customer’s behalf in a segregated wallet at its qualified custodian, retaining legal and beneficial ownership throughout; only the wallet ID, not custody or title, is shared with the Canton Foundation. Because the CC is never transferred to the customer, it continues to be accounted for under the Company’s digital asset policy for the full arrangement term. Each arrangement is a contract with a single customer - the Super Validator or Featured Application - containing one performance obligation: a stand-ready obligation to keep the agreed CC balance locked and verifiable throughout the term. Consistent with ASC 606-10-25-27 through 25-29, this obligation is satisfied over time, as the customer simultaneously receives and consumes the benefit of continuous, verifiable locking. The Company is compensated under one of three structures: (i) a stated daily interest rate on the locked CC balance; (ii) a percentage of the customer’s Canton Network rewards, net of an expense offset in certain cases; or (iii) a grant of equity in the customer, earned ratably over a one-year term. LAAS revenue is reported within Other revenue in the condensed consolidated statements of operations.

 

F-6

 

 

Interest / loan-type arrangements - Daily consideration is a fixed quantity of CC (rate × locked balance) that does not vary once accrued. This is noncash consideration under ASC 606-10-32-21 through 32-24; because the CC quantity itself is fixed, no variable-consideration constraint applies under ASC 606-10-32-11 through 32-13, as any resulting USD variability is attributable solely to the form of consideration (ASC 606-10-32-24). Revenue is recognized daily at fair value using that day’s end-of-day CC/USD reference rate, consistent with the right-to-invoice expedient (ASC 606-10-55-18), regardless of whether the counterparty ultimately settles in CC or USD. LAAS revenue from interest-type arrangements for the three and nine months ended September 30, 2026 was $863,504 and $1,273,548, respectively.

 

Revenue share arrangements - The Company’s percentage of monthly Canton Network rewards, net of any expense offset, is not fixed or determinable until month-end. Consistent with ASC 606-10-32-11 through 32-13, no interim estimate is recognized; revenue is recognized once, at month-end, in the finalized amount, translated at the month-end reference rate. Under one revenue share arrangement, the Company pays the customer a fixed monthly operator fee of $10,000, which is presented as a reduction of the related revenue; such fees totaled $50,000 for the nine months ended September 30, 2026. LAAS revenue from revenue share arrangements for the three and nine months ended September 30, 2026 was $578,109 and $1,465,131, respectively, net of such fees.

 

Equity compensation arrangement - Consideration is an equity grant measured at estimated fair value at contract inception under ASC 606-10-32-21 through 32-24, with subsequent changes in the equity’s value excluded from the transaction price per ASC 606-10-32-24. Revenue is recognized straight-line over the twelve-month service term, with a corresponding contract asset recognized until the equity is issued. LAAS revenue from equity compensation arrangements for the three and nine months ended September 30, 2026 was $31,250 and $41,667, respectively.

 

As of September 30, 2026, receivables from LAAS customers were $529,112, of which $526,256 was denominated in CC, less an allowance for credit losses of $10,259, and the contract asset arising from the equity compensation arrangement was $41,667. These balances are included in prepaid expenses and other current assets on the condensed consolidated balance sheets. The Company had no receivables or contract assets from contracts with customers as of December 31, 2025.

 

Derivatives – Option Contracts

 

During the quarter ended June 30, 2026, the Company began entering into CC-denominated option contracts through the sale of collateral-secured put options, as a part of its digital asset strategy. These contracts meet the definition of derivative instruments under ASC 815, Derivatives and Hedging. The Company does not designate derivative instruments as hedging instruments for accounting purposes.

 

The Company accounts for its CC-referenced option contracts as derivative instruments and recognizes them on the condensed consolidated balance sheets as assets or liabilities at fair value, with subsequent changes in fair value recognized in earnings. Premiums paid or received at contract inception are included in the initial fair value of the derivative instrument. If an option contract is exercised, the related derivative asset or liability is derecognized upon settlement. If an option contract expires unexercised, the related derivative asset or liability is derecognized upon expiration. Gains and losses related to CC option contracts, including fair value remeasurement and settlements, are recorded within Other revenue in the condensed consolidated statements of operations.

 

CC options are not currently exchange traded, and the fair value of CC option contracts is determined using OTC dealer prices. The OTC dealer prices are classified within level 2 of the fair value hierarchy.

 

The Company is required to post collateral with counterparties in connection with its CC option contracts, typically in the form of cash. Collateral posted is accounted for separately from the related derivative instrument and is not offset against derivative assets or liabilities. Collateral posted is presented within prepaid expenses and other current assets on the condensed consolidated balance sheets as the CC option contracts are less than 12 months duration. Cash flows associated with collateral on CC option contracts are reported as investing activities in the consolidated statements of cash flows.

 

F-7

 

 

As of September 30, 2026, the Company had no outstanding CC option contracts. For the three and nine months ended September 30, 2026, the Company recognized net gains of $75,131 and $72,281, respectively, on CC option contracts, recorded within Other revenue in the condensed consolidated statements of operations.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Areas of the consolidated financial statements where estimates may have the most significant effect include fair value of cryptocurrency, research and development expense recognition, valuation of common shares and share-based compensation, allowances of deferred tax assets, valuation of debt related instruments, expected credit losses on the note receivable, and cash flow assumptions regarding going concern considerations. Although management believes the estimates that have been used are reasonable, actual results could vary from the estimates that were used.

 

Reportable Segments

 

The Company had two reportable segments: digital asset treasury and clinical stage bio-technology. The digital asset treasury segment operates a CC-centric digital asset treasury strategy. The clinical stage bio-technology segment developed therapeutic candidates for rare, inflammatory and oncologic conditions through Gravitas, which was sold in the Gravitas Transaction on July 17, 2026 (see Note 10). The clinical stage bio-technology segment, other than the Oncology Program retained by the Company, is reported as discontinued operations. See Note 9 for additional information on the Company’s segments.

 

Concentration of Credit Risk

 

The Company maintains cash balances with various financial institutions. Account balances at these institutions are insured by the Federal Deposit Insurance Corporation up to $250,000 per depositor. At various times during the year, bank account balances may have been in excess of federally insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents, if any, are stated at cost and consist primarily of money market accounts.

 

Note Receivable and Allowance for Credit Losses

 

The note receivable represents the unsecured promissory note received from Gravitas Collective Corp., a Delaware corporation (“Buyer”), and Gravitas, as joint and several makers, pursuant to the Securities Purchase Agreement dated July 17, 2026 between the Company and Buyer (the “Purchase Agreement”) in connection with the Gravitas Transaction (the “Gravitas Note”; see Note 10). Buyer is a related party of the Company (see Note 8). The Gravitas Note bears interest at 15% per annum, which accrues as payment-in-kind interest and is capitalized to principal semi-annually, and matures on July 17, 2029, subject to optional and mandatory prepayment as described in Note 10. The Gravitas Note is held for investment and is recorded at amortized cost, consisting of principal and accrued payment-in-kind interest, net of any allowance for credit losses, and is presented as note receivable (related party) on the condensed consolidated balance sheets. Interest income is recognized on the accrual basis at the contractual rate and is included in interest income in the condensed consolidated statements of operations.

 

F-8

 

 

The Company measures expected credit losses on the Gravitas Note in accordance with ASC 326. Because the Company is not in the business of extending credit and has no loss history on receivables of this kind, the Gravitas Note is evaluated on an individual basis over its contractual term using external corporate default and recovery data adjusted for the specific characteristics of the Gravitas Note, including the makers’ financial condition and sources of repayment, the mandatory prepayment provisions and the unsecured nature of the Gravitas Note. The estimate is reassessed each reporting period.

 

As of September 30, 2026, the amortized cost basis of the Gravitas Note was $3,606,997, including accrued payment-in-kind interest of $106,997. The Company estimated expected credit losses on the Gravitas Note as of September 30, 2026 and concluded that the amount was not material. Accordingly, no allowance for credit losses was recorded as of September 30, 2026 and no credit loss expense was recognized for the three and nine months ended September 30, 2026.

 

Under the Purchase Agreement, the Company is also entitled to cash milestone payments of up to $3,000,000 in the aggregate upon the achievement by Buyer or Gravitas of specified clinical development and regulatory approval milestones (the “Milestone Payments”; see Note 10).

 

Digital Assets

 

The Company accounts for its digital assets, which are comprised of CC, as intangible assets in accordance with ASC 350-60, Intangibles-Goodwill and Other-Crypto Assets. The Company’s digital assets are initially recorded at cost, which for CC received from investors, earned through network validation rewards or received from LAAS customers is the fair value of the CC on the date the Company obtains control of it, and subsequently measured at fair value with the gain or loss associated with remeasurement of the digital assets recognized in net income (loss) during each reporting period. Upon disposal of a digital asset (e.g., by sale, exchange or transfer), the Company derecognizes the asset and recognizes a realized gain or loss in net income, calculated as the difference between the consideration received and the asset’s carrying amount.

 

The fair value of the Company’s digital assets is determined based on quoted prices in its principal market at the time of measurement. The Company determines its principal market as the market that it has access to and has the greatest volume and level of orderly transactions in accordance with FASB ASC 820, Fair Value Measurement. The Company tracks the cost of its digital assets using the first-in-first-out (FIFO) method.

 

Digital Asset Receivables

 

The Company enters into contracts with customers for LAAS arrangements where settlement is denominated in CC. CC denominated receivables are remeasured at fair value during each reporting period with any associated gain or loss recognized in net income. The Company analogizes CC denominated receivables to a foreign currency denominated monetary asset under ASC 830. The Company determines fair value of CC receivables using the same pricing basis as digital assets under ASC 350-60.

 

Research and Development

 

Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials, and manufacture drug supplies and materials. These expenses also include costs associated with license fee arrangements and collaboration agreements, including milestone payments and ongoing license fees, which are also expensed as incurred. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the services completed.

 

F-9

 

 

Stock-Based Compensation

 

The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees, and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of common stock issued pursuant to termination agreements as well as restricted stock or restricted stock units is generally measured as the grant-date price of the Company’s common stock. The fair value of each option grant to employees, non-employees, and directors is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on the straight-line basis over the requisite service period of the awards, which is generally the vesting period.

 

Prior to January 12, 2022, the Company was a private company and the Company’s common stock has only been publicly traded since that date. As a result, the Company has limited company-specific historical and implied volatility information. Therefore, it has estimated its expected stock volatility based on the historical data of a publicly traded set of peer companies. The expected term of stock options granted was between five and seven years. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant for time periods approximately equal to the expected term of the award.

 

Fair Value Measurements

 

The Company applies FASB ASC Topic 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.

 

The carrying value of the Company’s cash, prepaid expenses, accounts payable, and accrued expenses approximate fair value because of the short-term maturity of these financial instruments.

 

The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:

 

  Level 1 Inputs: Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
   
  Level 2 Inputs: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for assets or liabilities recently traded in active markets, with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals, as well as quoted prices for identical or similar assets or liabilities in markets that are not active.
   
  Level 3 Inputs: Unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities, that reflect the reporting entity’s own assumptions.

 

The Company applies ASC 820 in the valuation of CC held by the Company for financial statement purposes. The fair value of CC uses Level 1 inputs to reflect the price that would be received for CC in a current sale, which assumes an orderly transaction between market participants on the measurement date in CC’s “principal market,” or in the absence of a principal market, the most advantageous market. Market participants are defined as buyers and sellers in the principal or most advantageous market that are independent, knowledgeable, and willing and able to transact. The Company determines its principal market (or in the absence of a principal market, the most advantageous market) on a periodic basis to determine which market is its principal market for the purpose of calculating fair value for the creation of quarterly and annual financial statements. Issuer-specific events, market trends, bid/ask quotes of brokers and information providers and other data may be reviewed in the course of making a good faith determination of the digital asset’s fair value.

 

F-10

 

 

The following table presents the Company’s assets measured at fair value on a recurring basis, by level within the fair value hierarchy, as of September 30, 2026 and December 31, 2025:

 

   Level 1   Level 2   Level 3   Total 
                 
September 30, 2026                    
Digital assets – CC  $482,149,407   $-   $-   $482,149,407 
                     
December 31, 2025                    
Digital assets – CC  $501,760,369   $-   $-   $501,760,369 

 

The Company had no liabilities measured at fair value on a recurring basis as of September 30, 2026 or December 31, 2025, and there were no transfers between levels of the fair value hierarchy during the nine months ended September 30, 2026.

 

Income Taxes

 

The Company accounts for income taxes using the asset-and-liability method in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.

 

Deferred income taxes are recognized for the tax effect of temporary differences between the financial statement carrying amount of assets and liabilities and the amounts used for income tax purposes and for certain changes in valuation allowances. Valuation allowances are recorded to reduce certain deferred tax assets when, in management’s estimation, it is more-likely-than-not that a tax benefit will not be realized. A full valuation allowance has been recognized for all periods since it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods.

 

The Company follows the guidance in FASB ASC Subtopic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more-likely-than-not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. At September 30, 2026 and December 31, 2025, the Company had no unrecognized uncertain income tax positions, and therefore no amounts have been recognized in the consolidated financial statements.

 

Patent Costs

 

Costs associated with the submission of patent applications, including milestone fees and success fees, are expensed as incurred given the uncertainty of the future economic benefits of the patents. Patent and patent related legal and administrative costs are included in general and administrative expenses in the accompanying consolidated statements of operations.

 

Net Loss per Share

 

The Company reports loss per share in accordance with FASB ASC Subtopic 260-10, Earnings Per Share, which provides for calculation of basic and diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.

 

F-11

 

 

Potentially dilutive securities not included in the computation of loss per share for the nine months ended September 30, 2026 and 2025 are as follows:

 

       
   For the nine months ended September 30, 
   2026   2025 
         
Outstanding options to purchase shares of common stock   656,163    607,042 
Warrants to purchase shares of common stock   11,630,321    5,014,943 
Total potentially dilutive securities   12,286,484    5,621,985 

 

Recent Accounting Pronouncements

 

In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-08, Intangibles - Goodwill and Other - Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. This standard requires certain crypto assets meeting defined criteria to be measured at fair value each reporting period with changes in fair value recognized in net income, presented separately from other intangible assets and accompanied by enhanced disclosures. This standard was effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard during the year ended December 31, 2025 in conjunction with its new treasury strategy. Since the Company held no digital assets until November 2025, the adoption of this standard had no impact to prior reported financial statements and no cumulative adjustment to retained earnings was required or recorded.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires expanded segment reporting and disclosure and is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this guidance in the year ended December 31, 2025 as it previously did not have multiple reportable segments. This standard did not have a material impact on its financial statements other than enhanced disclosures.

 

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which expands income tax footnote disclosure requirements, including rate reconciliation and income taxes paid disclosures. The standard is effective for fiscal years beginning after December 15, 2024. The ASU affects disclosure only and does not impact the recognition or measurement of income taxes under ASC 740. Accordingly, adoption of ASU 2023-09 had no impact on the Company’s income tax provision.

 

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses and in January 2025, the FASB issued ASU No. 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarified the effective date of ASU 2024-03 for non-calendar year-end companies. ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the consolidated statements of operations, as well as qualitatively describe remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company’s definition of selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 31, 2027. The Company is currently evaluating the effects of the pronouncement on its consolidated financial statements.

 

F-12

 

 

Note 3 – Digital Assets

 

The following table sets forth the units held, cost basis, and fair value of CC held, as shown on the consolidated balance sheet as of September 30, 2026 and December 31, 2025:

 

   September 30, 2026   December 31, 2025 
         
Canton Coin          
Units held   3,833,830,293    3,339,567,946 
Cost basis  $597,592,216   $523,770,731 
Fair value  $482,149,407   $501,760,369 

 

Cost basis is equal to the cost of the digital asset, net of any transaction fees, if any, at the time of purchase or upon receipt. Fair value represents the quoted digital assets prices within the Company’s principal market at the time of measurement.

 

The following table presents a reconciliation of digital assets held as of September 30, 2026:

 

      
Fair value, December 31, 2025 balance  $501,760,369 
Additions from CC purchases   69,842,182 
Additions from CC receipts on network validation and other income   3,979,303 
Unrealized gains (losses)   (93,432,447)
      
Fair value, September 30, 2026 balance  $482,149,407 

 

Additions from CC receipts represent CC received during the period as network validation rewards and as consideration under LAAS arrangements. Non-cash revenue of $4,512,232 reported in the condensed consolidated statements of cash flows for the nine months ended September 30, 2026 exceeds CC receipts of $3,979,303 by $532,929, which consists of CC-denominated receivables of $526,256 and equity consideration of $41,667 earned under LAAS arrangements but not received as of September 30, 2026 (see Note 2), less a remeasurement gain of $34,994 on CC-denominated receivables. The unrealized loss from digital assets holdings of $93,397,453 in the condensed consolidated statements of operations consists of the $93,432,447 loss on remeasurement of CC held, net of the $34,994 remeasurement gain on CC-denominated receivables.

 

Note 4 – Common Stock

 

Pursuant to the Company’s Certificate of Incorporation, as amended (filed October 10, 2025), the Company has 1,000,000,000 (previously 250,000,000) shares of common stock authorized for issuance.

 

On November 3, 2025, the Company entered into securities purchase agreements (the “Cash Securities Purchase Agreements”) with certain accredited investors (the “Cash Purchasers”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “Cash Offering”) an aggregate of 25,966,048 shares of common stock of the Company (the “Cash Shares”) and/or pre-funded warrants (the “Cash Pre-Funded Warrants”) to purchase 6,351,021 shares of common stock (the “Cash Pre-Funded Warrant Shares”) at an offering price of $3.075 per share (the “Per Share Cash Purchase Price”) for gross proceeds of approximately $99.4 million. Each of the Cash Pre-Funded Warrants is immediately exercisable for one share of common stock subject to certain beneficial ownership limitations set forth therein.

 

Additionally, on November 3, 2025, the Company entered into securities purchase agreements (the “Cryptocurrency Securities Purchase Agreements”) with certain accredited investors (the “Cryptocurrency Purchasers”) pursuant to which the Company agreed to sell in a private placement (the “Cryptocurrency Offering”) pre-funded warrants (the “Cryptocurrency Pre-Funded Warrants”) to purchase 145,105,094 shares of common stock at an offering price of $3.075 for gross proceeds in Canton Coin of approximately $446.2 million. The Cryptocurrency Purchasers tendered Canton Coin to the Company as consideration for the Cryptocurrency Pre-Funded Warrants. Net proceeds to the Company from the combined Cash Offering and Cryptocurrency Offering were approximately $537.1 million after deducting $8.5 million in offering costs. Both the Cash Offering and Cryptocurrency Offering closed on November 6, 2025.

 

F-13

 

 

In conjunction with the Cash Securities Purchase Agreements and the Cryptocurrency Securities Purchase Agreements, the Company issued strategic advisor warrants to purchase up to 10,318,215 shares of the Company’s common stock, exercisable at $0.001 per share (the “Strategic Advisor Warrants”). In accordance with Nasdaq Listing Rule 5635(a), the issuance of shares pursuant to the Strategic Advisor Warrants were approved by shareholders on January 30, 2026.

 

On November 6, 2025, the Company entered into an at-the-market agreement (the “2025 ATM Agreement”) with Clear Street LLC (“Clear Street”) and President Street Global LLC (the “ATM Sales Agents”) under which the Company may sell, from time to time through the ATM Sales Agents, shares of common stock in one or more offerings up to a total dollar amount of $65 million. On December 3, 2025 President Street Global LLC provided notice to the Company terminating participation in the 2025 ATM Agreement, leaving Clear Street as the sole ATM Sales Agent. Sales of shares of the Company’s common stock through the ATM Sales Agent, if any, will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities, including, without limitation, sales made directly on the Nasdaq Stock Market LLC or any other existing trading market for the common shares. The Company’s common stock was being offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 and an accompanying prospectus declared effective by the SEC on March 24, 2023, and pursuant to a prospectus supplement dated November 7, 2025. As of December 31, 2025, the Company had sold 1,657,799 shares of common stock pursuant to the 2025 ATM Agreement for net proceeds of approximately $5.1 million after deducting commissions of approximately $0.1 million.

 

On January 21, 2026, the Company closed an underwritten offering for 1,800,000 shares of its common stock, par value $0.0001 per share at an offering price of $2.92 per share and pre-funded warrants to purchase up to 17,000,000 shares of common stock at an offering price of $2.9199 per pre-funded warrant. The exercise price of each pre-funded warrant is $0.0001 per share (the “January 2026 Offering”). Net proceeds to the Company for the January 2026 Offering were approximately $52.7 million after deducting $2.2 million in offering costs.

 

The January 2026 Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (Registration Statement No. 333-292648), including the prospectus included therein, previously filed with the SEC and which became effective on January 16, 2026, and a prospectus supplement and the accompanying prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act.

 

On February 18, 2026, the Company’s common stock began trading under the ticker symbol, “CNTN.”

 

On March 3, 2026, the Company entered into an amended and restated sales agreement (the “March 2026 ATM Agreement”), with Clear Street and Virtu Americas LLC (“Virtu”, and together with Clear Street, the “Sales Agents”), relating to the sale of shares of the Company’s common stock. The sales agreement amends and restates the 2025 ATM Agreement. Pursuant to the March 2026 ATM Agreement, the aggregate gross sales price of common stock available for issuance under the March 2026 ATM Agreement is $300,000,000 and such amount excludes the common stock previously sold under the 2025 ATM Agreement. The Company’s common stock is being offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration Statement No. 333-292648), including the prospectus included therein, previously filed with the SEC which became effective on January 16, 2026. During the three and nine months ended September 30, 2026, the Company sold 369,125 and 9,483,463 shares of common stock, respectively, pursuant to the 2025 ATM Agreement and the March 2026 ATM Agreement for net proceeds of approximately $0.9 million and $40.1 million, respectively, after deducting commissions and offering costs of approximately $0.6 million for the nine months ended September 30, 2026.

 

During the nine months ended September 30, 2026, the Company also incurred $834,775 of issuance costs that are presented separately in the condensed consolidated statements of changes in stockholders’ equity, consisting of $501,200 of SEC registration and FINRA filing fees for the Company’s $2.0 billion shelf registration statement on Form S-3, $261,413 of legal fees related to the January 2026 Offering, and $72,162 of other legal and accounting fees related to the Company’s registration statements. These costs were recorded as a reduction of additional paid-in capital.

 

F-14

 

 

Note 5 – Stock Based Compensation

 

Incentive Plans and Options

 

Under the Company’s 2017 Stock Incentive Plan (the “2017 Plan”) the Company could grant incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares, and performance units to employees, directors, and consultants of the Company and its affiliates. Up to 261 shares of the Company’s common stock could be issued pursuant to the 2017 Plan.

 

The Company granted options to acquire 255 shares of common stock at $4,950 per share under the 2017 Plan. During the nine months ended September 30, 2026, options to acquire 120 shares of common stock were forfeited. At September 30, 2026 there were no options outstanding under the 2017 Plan. At December 31, 2025, there were 120 options outstanding to acquire shares of common stock.

 

In July 2019, the Company authorized the 2019 Stock Incentive Plan (the “2019 Plan”). Under the 2019 Plan, the Company could grant incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares, and performance units to employees, directors, and consultants of the Company and its affiliates.

 

The Company granted options to acquire 10,452 shares of common stock under the 2019 Plan, of which 4,940 were exercised. During the nine months ended September 30, 2026, options to acquire 759 shares of common stock were forfeited. There are stock options outstanding to acquire 134 shares of common stock with a weighted-average exercise price of $498.75 and weighted average contractual terms of 5.5 years at September 30, 2026. At December 31, 2025 there were 893 options outstanding to acquire shares of common stock.

 

On August 17, 2023, the Company authorized the Tharimmune, Inc. 2023 Omnibus Incentive Plan (as amended, the “2023 Plan”). Under the 2023 Plan, the Company may grant incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares, and performance units to employees, directors, and consultants of the Company and its affiliates. Under an amendment and restatement to the 2023 Plan approved by the Company’s stockholders on May 14, 2024, an “evergreen” provision was added to automatically increase the number of shares available under the 2023 Plan on January 1 annually, beginning January 1, 2025 and ending January 1, 2033, equal to the lesser of five percent of the shares of common stock outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year or such lesser number of shares of the Company’s common stock as determined by the Board of Directors. Effective January 1, 2025, an additional 98,688 shares of the Company’s common stock were added to the 2023 Plan, effective June 10, 2025, the shareholders approved an amendment to the 2023 Plan, increasing the 2023 Plan by 520,314 shares, effective October 9, 2025, the shareholders approved an additional amendment to the 2023 Plan, increasing the 2023 Plan by 1,207,398 shares, to a total of 2,000,000 shares available under the 2023 Plan. On January 30, 2026 shareholders approved an amendment to the 2023 Plan, increasing the shares authorized by 7,000,000 to a total of 9,000,000. 7,793,342 and 802,671 shares of common stock remained available for issuance under the 2023 Plan as of September 30, 2026 and December 31, 2025, respectively.

 

During the nine months ended September 30, 2026 and 2025, the Company granted 0 and 648,833 options to acquire shares of common stock under the 2023 Plan, respectively. During the nine months ended September 30, 2026 and 2025, options to acquire 0 and 145,992 shares of common stock were forfeited under the 2023 Plan, respectively, and there were no exercises. As of September 30, 2026 there were stock options outstanding to acquire 656,029 shares of common stock with a weighted-average exercise price of $1.94 and weighted-average contractual terms of 8.8 years.

 

The following table summarizes stock-based activities under the 2017 Plan, 2019 Plan, and 2023 Stock Incentive Plans:

 

   Shares Underlying Options   Weighted Average Exercise Price   Weighted Average Contractual Terms 
             
Outstanding at December 31, 2025   657,042   $4.32    9.5 years 
Forfeited   (879)  $1,626.87    N/A 
Outstanding at September 30, 2026   656,163   $2.04    8.8 years 
Exercisable options at September 30, 2026   656,163   $2.04    8.8 years 
                
Vested and expected to vest at September 30, 2026   656,163   $2.04    8.8 years 

 

F-15

 

 

The fair value of stock option awards is estimated at the date of grant using the Black-Scholes option-pricing model. The estimated fair value of each stock option is then expensed over the requisite service period, which is generally the vesting period (ranging between immediate vesting and four years). The determination of fair value using the Black-Scholes model is affected by the Company’s share price as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, expected life, risk-free interest rate and forfeitures. Forfeitures are accounted for as they occur.

 

Stock options granted during the nine months ended September 30, 2026 and 2025 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions:

 

   For the nine months ended September 30, 
   2026   2025 
         
Expected volatility   N/A    95.7 - 102.3%
Risk-free interest rate   N/A    3.75 - 4.61%
Expected dividend yield   N/A    0%
Expected life of options in years   N/A    5.0 
Estimated fair value of options granted   N/A    $0.99 - 1.50 

 

There were no options granted in the nine months ended September 30, 2026. The weighted-average grant date fair value of stock options granted during the nine months ended September 30, 2025 was approximately $1.09. There were no options that vested in the nine months ended September 30, 2026. All options granted were fully vested as of December 31, 2025. The weighted-average fair value of stock options vested during the three and nine months ended September 30, 2025 was approximately $1.00 and $2.21, respectively.

 

As of September 30, 2026, there was no unrecognized compensation expense related to non-vested options.

 

Warrants

 

The Company has issued warrants to purchase shares of common stock in connection with various offerings, including those described in Note 4. The exercise of the Cryptocurrency Pre-Funded Warrants into common stock was subject to shareholder approval, and was approved on January 30, 2026 at a special meeting.

 

The Strategic Advisor Warrants are compensatory and the issuance of shares pursuant to their exercise was approved by shareholders on January 30, 2026 so the Company recorded $31,728,511 of stock-based compensation expense for the nine months ended September 30, 2026. The Strategic Advisor Warrants were valued at $3.075, the per share offering price of the Cash Offering and Cryptocurrency Offering which closed on November 6, 2025.

 

F-16

 

 

Terms of the warrants outstanding at September 30, 2026 are as follows: 

 

Issuance Date  Initial Exercise Date  Expiration Date  Exercise Price   Warrants Issued   Warrants Exercised   Warrants Outstanding 
                       
January 14, 2022  July 10, 2022  January 11, 2027  $1,875.00    500    -    500 
                           
May 2, 2023  November 2, 2023  May 2, 2028  $234.375    424    -    424 
                           
November 30, 2023  May 27, 2024  May 2, 2028  $18.75    20,000    -    20,000 
                           
June 21, 2024  June 21, 2024  N/A  $0.001    452,253    452,253    - 
                           
June 21, 2024  June 21, 2024  December 21, 2029  $3.09    329,771    229,430    100,341 
                           
June 21, 2024  June 21, 2024  December 21, 2029  $3.06    39,573    -    39,573 
                           
December 9, 2024  December 9, 2024  N/A  $0.001    491,157    491,157    - 
                           
December 9, 2024  June 9, 2025  December 9, 2030  $2.03    480,721    317,673    163,048 
                           
December 9, 2024  June 9, 2025  December 9, 2030  $2.031    57,687    -    57,687 
                           
June 20, 2025  June 20, 2025  N/A  $0.001    137,838    137,838    - 
                           
June 20, 2025  December 20, 2025*  June 20, 2031*  $1.29    1,689,189    891,895    797,294 
                           
June 20, 2025  December 20, 2025*  June 20, 2031*  $3.00    844,570    114,862    729,708 
                           
June 20, 2025  December 20, 2025  June 20, 2031  $1.29    118,243    6,739    111,504 
                           
June 20, 2025  December 20, 2025  June 20, 2031  $3.00    59,119    -    59,119 
                           
July 25, 2025  July 25, 2025  N/A  $0.001    559,910    559,910    - 
                           
July 25, 2025  January 25, 2026*  July 25, 2031*  $1.66    974,241    288,350    685,891 
                           
July 25, 2025  July 25, 2025  N/A  $0.001    103,490    103,490    - 
                           
July 25, 2025  January 25, 2026*  July 25, 2031*  $1.52    744,680    699,088    45,592 
                           
July 25, 2025  January 25, 2026  July 25, 2031  $1.66    52,128    2,971    49,157 
                           
August 26, 2025  August 26, 2025  N/A  $0.001    983,111    983,111    - 
                           
November 6, 2025  November 6, 2025  N/A  $0.001    6,351,021    -    6,351,021 
                           
November 6, 2025  November 6, 2025  N/A  $0    145,105,094    30,823,808    114,281,286 
                           
November 6, 2025  January 30, 2026  January 30, 2031  $0.001    10,318,215    1,547,732    8,770,483 
                           
January 21, 2026  January 21, 2026  N/A  $0.0001    17,000,000    -    17,000,000 

 

*The exercise and expiration dates for the referenced common warrants were amended in October 2025 to reflect an exercise date of October 1, 2025.

 

F-17

 

 

Restricted Stock Units

 

During the nine months ended September 30, 2025, as stock-based consideration for consulting services, the Company granted restricted stock units (“RSUs”) under the 2023 Plan representing the right to receive 35,000 shares of the Company’s common stock, with a grant date fair value of $1.975 per RSU, vesting on June 30, 2026. During the nine months ended September 30, 2026, as stock-based consideration for consulting services, the Company granted RSUs under the 2023 Plan representing the right to receive 15,000 shares of the Company’s common stock, with a grant date fair value of $5.13 per RSU, vesting on June 30, 2026. All of the RSUs fully vested on June 30, 2026, and no RSUs were outstanding at September 30, 2026. As of September 30, 2026, the 15,000 shares of common stock underlying the RSUs granted in 2026 had vested but had not yet been issued, and the Company remains obligated to issue such shares.

 

The grant date fair value of an RSU represents the closing price of the Company’s common stock on the date of grant. For those not vesting immediately, the estimated fair value of each RSU is then expensed over the requisite service period, which is generally the vesting period.

 

The total stock compensation expense related to RSUs for the three and nine months ended September 30, 2026 was $0 and $101,104, respectively, and for the three and nine months ended September 30, 2025 was $12,277 and $32,694, respectively. The expense for the nine months ended September 30, 2026 consisted of $24,154 related to the RSUs granted in January 2025 and $76,950 related to the RSUs granted in February 2026.

 

During the nine months ended September 30, 2026 the Company issued restricted stock units, representing the rights to receive 162,601 shares of common stock to Clear Street LLC in connection with its services as an advisor in the Cash Offering and Cryptocurrency Offering which closed on November 6, 2025 (the “Advisor RSUs”). The issuance of Advisor RSUs and the underlying common stock were approved by shareholders during a special meeting on January 30, 2026. The Advisor RSUs were valued at $3.075 per share, the per share offering price of the Cash Offering and Cryptocurrency Offering which closed on November 6, 2025. The Company recorded $499,998 of stock compensation expense related to the Advisor RSUs for the nine months ended September 30, 2026.

 

Total stock-based compensation expense included in the accompanying consolidated statements of operations was as follows:

 

             
   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2026   2025   2026   2025 
                 
Discontinued Operations  $-   $93,643   $-   $449,541 
General and administrative   -    433,371    32,329,613    864,288 
Total stock-based compensation  $-   $527,014   $32,329,613   $1,313,829 

 

Note 6 – Income Taxes

 

The following table presents the income tax provision (benefit) and effective tax rate:

  

   Three Months Ended September 30, 
   2026   2025 
         
Income tax provision (benefit)   (15,327,449)   - 
Effective tax rate   28.4%   - 

 

   Nine Months Ended September 30, 
   2026   2025 
           
Income tax provision (benefit)   (26,219,864)   - 
Effective tax rate   20.4%   - 

 

The effective tax rate reflects a full valuation allowance against net deferred tax assets, including tax loss carryforwards. The Company has recognized a deferred tax provision (benefit) in connection with unrealized gains or losses on Digital Assets.

 

F-18

 

 

Note 7 – Commitments and Contingencies

 

Research Collaboration and Product License Agreement with Minotaur Therapeutics, Inc. (“Minotaur”) and Commercial License Agreement with Taurus Biosciences, LLC (“Taurus”)

 

The Company has entered into a research collaboration and product license agreement with Minotaur (as amended, the “Minotaur Agreement”) and a commercial license agreement with Taurus (the “Taurus Agreement”) for use of certain technology, including OmniAb antibodies, to advance Picobodies against novel, unreachable, and undruggable epitopes in high-value validated targets starting with PD-1. The Minotaur Agreement and Taurus Agreement are for the development of proprietary targeted biologics, including HS1940, against PD-1. Pursuant to the Minotaur Agreement the Company can collaborate with Minotaur under the license from Taurus to discover, develop, and advance biotherapeutics against high-value validated IO targets starting with PD-1.

 

The Minotaur Agreement included an up-front payment of $150,000, which was paid in January 2023. In addition, the Company shall fund the discovery and characterization study performed by Minotaur as set forth in the Minotaur Agreement. Pursuant to the Minotaur Agreement, the Company is required to pay Minotaur a milestone payment of $1,000,000 for each first Product (as defined in the Minotaur Agreement) directed against a target and first regulatory approval in the U.S. In addition, the Company is required to pay a low single digit royalty on net sales until the later of (i) ten years after the First Commercial Sale (as defined in the Minotaur Agreement) of such Product in such country and (ii) the expiration of the last-to-expire Valid Claim (as defined in the Minotaur Agreement) of a Collaboration Patent (as defined in the Minotaur Agreement) or MINT Patent (as defined in the Minotaur Agreement) covering the manufacture, use, or sale of such Product. The Taurus Agreement contains single digit payments on net product sales and certain development milestone payments tied to the advancement through clinical trials and final regulatory approval.

 

Research and Development Collaboration and License Agreement with Applied Biomedical Science Institute

 

On July 5, 2023 (the “ABSI Effective Date”), the Company entered into a Research and Development Collaboration and License Agreement (the “ABSI Agreement”) with ABSI pursuant to which ABSI granted the Company an exclusive royalty-bearing, sublicensable license to the ABSI Patents (as defined in the ABSI Agreement) and a non-exclusive, royalty-bearing, sublicensable license to the ABSI Know-How (as defined in the ABSI Agreement) to Exploit (as defined in the ABSI Agreement) the ABSI Products (as defined in the ABSI Agreement) for the treatment, diagnosis, prediction, detection or prevention of disease in humans and animals worldwide (the “Territory”).

 

Pursuant to the ABSI Agreement, the parties are required to form a committee to manage the preclinical, investigational new drug enabling studies and such other activities as shall lead to the initiation of a Phase 1 clinical trial of the ABSI Product. The parties can collaborate on a Target-by-Target basis to identify and evaluate ABSI Products directed against such Target (as defined below) with a view to identifying or generating suitable Products (as defined in the ABSI Agreement) for the Company to Exploit. “Target” means ErB2 (Her2) and ErbB3. Upon completion of the Discovery Timeline (as defined in the ABSI Agreement) for a Target, subject to the terms and conditions of ABSI Agreement, the Company may exclusively own any ABSI Products against such Target. In the event the committee determines that the discovery activities are unsuccessful with respect to a Target, the Company may propose an additional target, which, upon approval by ABSI, would replace a failed Target.

 

F-19

 

 

Pursuant to the ABSI Agreement: (i) the Company issued ABSI 25,107 shares of its common stock which is equal to $250,000 based on the ten day trailing volume weighted-average price of the Company’s common stock prior to the date of issuance, (ii) in the event the Company closes a financing pursuant to which it receives more than $10 million in Net Proceeds (as defined in the ABSI Agreement), the Company would pay ABSI a mid-six digit amount; (iii) upon the achievement of certain milestones as set forth in the ABSI Agreement, the Company would pay ABSI up to an aggregate of $8,250,000; (iv) after the second anniversary of the ABSI Effective Date, the Company would pay ABSI a low five digit amount for the first year and a mid-five digit amount thereafter during the Royalty Term (as defined in the ABSI Agreement); and (v) during the Royalty Term for each Product, the Company shall pay ABSI a quarterly royalty on the Net Sales (as defined in the ABSI Agreement) with royalties at percentages which range from the low to mid-single digits, with high Net Sales being subject to lower royalty rates, subject to adjustment as set forth in the ABSI Agreement. In addition, in the event the Company transfers all or substantially all of its rights to a Product to a third party, the Company would pay to ABSI the percentage of Net Proceeds attributable to the transfer of the Product. Specifically, the Company would pay ABSI amounts at percentages which range from the mid-single digit to low double digits depending on the Company Expenses (as defined in the ABSI Agreement), with higher Company Expenses being subject to lower rates.

 

On a Product-by-Product basis, upon the expiration of the last Royalty Term of such Product in the Territory, licenses granted to the Company with respect to such Product would be deemed non-exclusive, fully paid, royalty-free, perpetual and irrevocable. The ABSI Agreement would expire upon the expiration of the last Royalty Term of the last Product, unless such agreement is terminated earlier pursuant to its terms. The ABSI Agreement may also be terminated (i) by either the Company or ABSI for (A) a material breach of the ABSI Agreement or (B) bankruptcy, (ii) ABSI may terminate the ABSI Agreement upon the commencement of a Challenge Proceeding (as defined in the ABSI Agreement) or (iii) the Company may terminate the ABSI Agreement at any time upon 90 days prior written notice to ABSI. Upon termination or expiration of the ABSI Agreement other than as a result of a bankruptcy or Challenge Proceeding, all licenses granted to the Company pursuant to such agreement will terminate and all rights under such licenses would revert to ABSI.

 

On March 11, 2024, the Company entered into an addendum to the ABSI Agreement to fund research services with quarterly payments of $50,000 beginning March 18, 2024 with subsequent payments due on the 18th of each calendar quarter. Effective July 31, 2025, the quarterly services agreement was terminated. During the three and nine months ended September 30, 2026 the Company incurred no research service expense under the ABSI Agreement, and during the three and nine months ended September 30, 2025, the Company incurred research service expense of $990 and $116,024, respectively. Expenses related to the ABSI Agreement are included in continuing operations and the ABSI agreement was retained by the Company following the Gravitas Transaction (see Note 10).

 

Avior Patent License Agreement

 

On November 3, 2023 (the “Avior Effective Date”), the Company entered into the Avior Patent License Agreement with Avior pursuant to which the Company received an exclusive sublicensable right and license to Licensed Patent Rights and Licensed Technology to, among other things, Develop, have Developed, make, have made, use, sell, import, export and commercialize TH104 and TH103 and to practice the Licensed Technology in connection with the foregoing, throughout the world. Pursuant to the Avior Patent License Agreement, the Company paid Avior an up front license fee of $0.4 million within ten days of the Avior Effective Date and a quarterly license fee of $0.15 million which was paid at the end of each fiscal quarter following the Avior Effective Date. In addition, the Company was to pay Avior a high single digit percentage of any upfront payments received by it as a result of the grant of any sublicenses with respect to TH104. The Company was also to pay Avior milestone payments in the aggregate amount of $27,250,000 upon the occurrence of various development milestones (the “Development Milestone Payments”). Furthermore, the Company was to pay Avior certain fees based upon sales milestones. The payments for such sales milestones ranged from the low seven digits to the low eight digits with higher sales being subject to higher fees. Finally, the Company was to pay Avior royalties based on net sales. Such royalties ranged from low single digit percentages to mid-single digit percentages with higher sales being subject to lower percentages. The Avior Patent License Agreement was to expire upon the expiration of the final payment obligation due to Avior as set forth in such agreement. Upon the expiration of the Avior Patent License Agreement, the Company was to have a fully paid, irrevocable, freely transferable and sublicensable worldwide license to the Licensed Patent Rights and Licensed Technology to Develop, have Developed, make, have made, use, have used sell, offer for sale, have sold, import, have imported, export, have exported, commercialize or have commercialized any and all Licensed Products and to practice the Licensed Technology worldwide. Pursuant to the Avior Patent License Agreement, the Company could terminate the agreement at any time without cause, upon 30 days’ prior written notice to Avior along with payment of the next unpaid Development Milestone Payment, if any. Furthermore, either the Company or Avior could terminate the Avior Patent License Agreement (i) on written notice to the other party if the other party materially breached any provision of the Avior Patent License Agreement and failed to cure such breach within 30 days after the breaching party received written notice thereof or (ii) on written notice in the event that either party (A) became insolvent or admitted its inability to pay its debts generally as they became due; (B) became subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law, which was not fully dismissed or vacated within 60 days; (C) was dissolved or liquidated or took any corporate action for such purpose; (D) made a general assignment for the benefit of creditors; or (E) had a receiver, trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business. Upon termination of the Avior Patent License Agreement, the license granted pursuant to such agreement would terminate and all rights in the Licensed Patent Rights and Licensed Products would revert back to Avior.

 

F-20

 

 

During the three and nine months ended September 30, 2026, the Company incurred fees under the license agreement to Avior of $0 and $214,500, respectively. During the three and nine months ended September 30, 2025 the Company incurred fees under the license agreement to Avior of $0 and $212,082, respectively. Fees incurred under the license agreement to Avior are reflected in discontinued operations.

 

Enkefalos License Agreement

 

On June 17, 2024 (the “Enkefalos Effective Date”), the Company signed a letter of intent to enter into the Enkefalos License Agreement with Enkefalos Biosciences Inc. (“Enkefalos”) pursuant to which the Company is licensing the global rights in all fields of use for the products related to the compounds known as cyclotides to deliver HER2 antibodies across the blood-brain barrier and all associated know-how, technology, intellectual property and related information and constructs, and any associated authorized generic rights and all related assets (collectively, the “Products” referred to in this letter as ENBI-01) from Enkefalos. This agreement was terminated during the nine months ended September 30, 2025. Pursuant to the Enkefalos License Agreement, the Company paid Enkefalos an up-front license fee of $150,000, included within research and development expenses, within ten days of the Enkefalos Effective Date. Upon termination of the Enkefalos License Agreement, the license granted pursuant to such agreement terminated and all rights in the Licensed Patent Rights and Licensed Products reverted back to Enkefalos.

 

During the three and nine months ended September 30, 2026 the Company incurred no license fees to Enkefalos. During the three months ended September 30, 2025 the Company incurred no license fees to Enkefalos, and during the nine months ended September 30, 2025 the Company recognized a credit of $150,000 to license fees to Enkefalos in accordance with the terms of the agreement. Fees incurred under the license agreement to Enkefalos are reflected in discontinued operations.

 

Intract Patent License Agreement

 

On September 11, 2024, the Company entered into the Intract Agreement pursuant to which the Company exclusively licensed INT-023/TH023, an oral anti-Tumor Necrosis Factor-alpha (TNF-α) monoclonal antibody infliximab. Under the terms of the Intract Agreement, the Company licensed global development and commercialization rights (outside of South Korea) to Intract’s Soteria® and Phloral® delivery platform along with an existing supply agreement for infliximab to be used in the oral product development program. Pursuant to the Intract Agreement, the Company paid Intract an up-front license fee of $0.4 million and Intract was eligible to receive additional payments upon an equity financing of the Company and additional payments for future development, regulatory and commercial milestones, as well as mid-single digit royalties based on net product sales. During the nine months ended September 30, 2025, the Company amended the Intract Agreement to change the payment terms of certain milestone fees, which increased the total milestone fees by $0.15 million. Pursuant to the Intract Agreement, the Company retained a right of first refusal to continue development and commercialization after a Phase 2 clinical trial. In addition, the Company had the option to exercise the license to Intract’s platform for up to four additional targets. The term of the Intract Agreement was to expire upon the final payment obligation of Canton Strategic Holdings, Inc. and could be terminated by Canton Strategic Holdings, Inc. at any time upon 90 days written notice to Intract. Either party could terminate the Intract Agreement if the other party materially breached any provision of the Intract Agreement and failed to cure such breach within 30 days after the breaching party received written notice thereof. In addition, either party could terminate the Intract Agreement on written notice in the event that either party: (a) became insolvent or admitted inability to pay its debts generally as they became due; (b) became subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law, which was not fully dismissed or vacated within 60 days; (c) was dissolved or liquidated or took any corporate action for such purpose; (d) made a general assignment for the benefit of creditors; or (e) had a receiver, trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business.

 

F-21

 

 

During the three and nine months ended September 30, 2026 the Company incurred fees of $0 and $53,535, respectively to Intract in accordance with the terms of the agreement. During the three and nine months ended September 30, 2025 the Company incurred fees of $0 and $150,337, respectively to Intract in accordance with the terms of the agreement. Fees incurred under the license agreement to Intract are reflected in discontinued operations.

 

Gravitas Purchase Agreement

 

In connection with the Gravitas Transaction, the Company agreed under the Purchase Agreement to indemnify Buyer and its affiliates, including Gravitas, for losses arising from any inaccuracy in or breach of the Company’s representations, warranties and covenants, subject to the survival periods and the limitation on aggregate liability set forth in the Purchase Agreement. Indemnifiable losses finally resolved in favor of Buyer are recoverable first by offset against earned but unpaid Milestone Payments, then against accrued interest and outstanding principal under the Gravitas Note, and thereafter directly from the Company. The Company has not recorded any liability in respect of its indemnification obligations under the Purchase Agreement as of September 30, 2026. See Note 10 for additional information regarding the Gravitas Transaction.

 

Note 8 – Related Party Transactions

 

The Company’s Chairman through year ended December 31, 2025 is a partner and licensed broker at President Street Global, a consultant for the Company. His combined ownership, both individually and through President Street Global and additional companies, is approximately 4% of the Company’s outstanding common stock, including common shares available upon exercise of warrants and vested options to purchase shares of the Company’s common stock. The Company incurred fees of $25,000 and $975,000 to President Street Global for services rendered during the three and nine months ended September 30, 2026, respectively. $25,000 and $625,000 of these fees are reflected in discontinued operations for the three and nine months ended September 30, 2026, respectively. The Company made payments of $600,000 and $1,500,000 to President Street Global for services rendered during the three and nine months ended September 30, 2025 respectively.

 

During the three and nine months ended September 30, 2026, the Company purchased $6,095,386 and $55,300,389 of CC in OTC transactions from an affiliate cryptocurrency liquidity provider under the control of a shareholder who beneficially owns more than 5% of the Company’s outstanding common stock.

 

On July 17, 2026, the Company sold Gravitas to Buyer in the Gravitas Transaction (see Note 10). Buyer is affiliated with Vincent LoPriore, Sireesh Appajosyula and Gary Stetz, former directors of the Company. The Gravitas Transaction was reviewed by a special committee of independent non-interested directors and, on July 15, 2026, was approved by the special committee and, upon its recommendation, by the full Board of Directors. The Company recognized a gain on sale of $3,719,882 within net income (loss) from discontinued operations and interest income of $106,997 on the Gravitas Note for the three and nine months ended September 30, 2026. At September 30, 2026, the carrying amount of the Gravitas Note due from Buyer and Gravitas was $3,606,997, and no Milestone Payments had become due. $1,125,000 of the Gravitas Note is presented within current assets, reflecting the prepayments received subsequent to the balance sheet date (see Note 11), and $2,481,997 is presented within non-current assets.

 

Note 9 – Segment Reporting

 

The Company has two reportable segments: digital asset treasury and clinical stage bio-technology. The Company identifies its reportable segments on the basis of its business activities, which is the basis on which operating results are reviewed and resources are allocated. The digital asset treasury segment acquires and holds CC and derives its revenues from Canton Network validation rewards and CC locking services. The clinical stage bio-technology segment developed therapeutic candidates for rare, inflammatory and oncologic conditions through Gravitas, which the Company sold in the Gravitas Transaction on July 17, 2026, and its results are reported as discontinued operations (see Note 10). There have been no changes in the basis of segmentation or in the basis of measurement of segment profit or loss from those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

 

F-22

 

 

The Company’s Chief Executive Officer serves as the Chief Operating Decision Maker (“CODM”) and evaluates the financial performance of the business and makes resource allocation decisions on the basis of net income/(loss) before income taxes. Summary segment financial performance measures evaluated by the CODM as of September 30, 2026 and December 31, 2025 and for the three and nine months ended September 30, 2026 and 2025:

 

Segment assets as of September 30, 2026 and December 31, 2025:

 

   September 30, 2026   December 31, 2025 
         
Digital asset treasury segment  $513,933,233   $513,964,900 
Clinical stage bio-technology segment – continuing operations   -    - 
Clinical stage bio-technology segment – held for sale (Note 10)   -    5,181,535 
           
Total assets  $513,933,233   $519,146,435 

 

Digital asset treasury segment

 

   2026   2025   2026   2025 
   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2026   2025   2026   2025 
                 
Income (loss) from operations  $340,591   $-   $(36,082,744)  $- 
Other income (expense) (a)   376,820    -    1,006,846    - 
Unrealized loss on digital assets holdings   (54,648,199)   -    (93,397,453)   - 
                     
Total loss before income taxes  $(53,930,788)  $-   $(128,473,351)  $- 

 

Clinical stage bio-technology segment

 

   2026   2025   2026   2025 
   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2026   2025   2026   2025 
                 
Loss from operations – continuing operations  $-   $(1,917,361)  $-   $(5,390,003)
Loss from operations – discontinued operations   (194,840)   (176,217)   (3,142,715)   (1,101,404)
Gain on sale of Gravitas – discontinued operations   3,719,882    -    3,719,882    - 
Other income (expense) (a)   -    (8,260)   -    (7,288)
                     
Total income (loss) before income taxes  $3,525,042   $(2,101,838)  $577,167   $(6,498,695)

 

(a)Other income (expense) consists of interest income and interest expense.

 

F-23

 

 

The following table is a reconciliation of segment total income (loss) before income taxes to our consolidated total loss before income taxes and to consolidated loss from continuing operations before income taxes.

 

   2026   2025   2026   2025 
   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2026   2025   2026   2025 
                 
Digital asset treasury segment total loss before income taxes  $(53,930,788)  $-   $(128,473,351)  $- 
Clinical stage bio-technology segment total loss before income taxes – continuing operations   -    (1,925,621)   -    (5,397,291)
Clinical stage bio-technology segment total income (loss) before income taxes – discontinued operations   3,525,042    (176,217)   577,167    (1,101,404)
Consolidated total loss before income taxes  $(50,405,746)  $(2,101,838)  $(127,896,184)  $(6,498,695)
Less: income (loss) before income taxes of discontinued operations (Note 10)   3,525,042    (176,217)   577,167    (1,101,404)
Consolidated loss from continuing operations before income taxes  $(53,930,788)  $(1,925,621)  $(128,473,351)  $(5,397,291)

 

Note 10 – Discontinued Operations

 

Description of the Gravitas Transaction

 

During the three months ended June 30, 2026, management committed to a plan for the divestiture of the Company’s wholly owned subsidiary, Gravitas, in order to focus the Company’s resources on its digital asset treasury strategy, and concluded in accordance with ASC 205-20 that the held for sale criteria under ASC 360-10-45-9 were met. Gravitas comprised the Company’s clinical stage bio-technology segment (see Note 9). On July 17, 2026, Gravitas Life Sciences, Inc. converted into a Delaware limited liability company, Gravitas Life Sciences, LLC, and the Company entered into the Purchase Agreement with Buyer, pursuant to which the Company sold to Buyer all of the issued and outstanding membership interests of Gravitas. The Gravitas Transaction closed on July 17, 2026. Prior to the closing, Gravitas transferred the assets related to the Oncology Program to Tharimmune SPV1, LLC, a wholly owned subsidiary of the Company; those assets had no carrying value at the date of transfer. Buyer is affiliated with former directors of the Company (see Note 8).

 

Assets and Liabilities Held for Sale

 

Summarized balance sheet information of assets and liabilities held for sale is below:

 

   September 30,   December 31, 
   2026   2025 
         
Cash and cash equivalents  $        -   $5,025,600 
Prepaid expenses and other current assets   -    155,935 
Current assets held for sale   -    5,181,535 
Total assets held for sale  $-   $5,181,535 
Accounts payable  $-   $569,073 
Accrued expenses   -    1,689,630 
Total current liabilities held for sale   -    2,258,703 
Total liabilities held for sale  $-   $2,258,703 

 

F-24

 

 

Results of Discontinued Operations

 

For periods prior to the Company’s transition to its digital asset treasury strategy in November 2025, discontinued operations include the research and development expenses of the clinical-stage business other than those of the HS1940 program, which is part of the retained Oncology Program, and continuing operations include the general and administrative expenses incurred by the Company as a public reporting entity. For periods after the transition, general and administrative expenses specifically attributable to Gravitas are included in discontinued operations.

 

The statement of operations of discontinued operations are summarized below:

 

   2026   2025   2026   2025 
   For the Three Months Ended
September 30,
   For the Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
                 
Research and development   38,492    176,217    718,082    1,101,404 
General and administrative   156,348    -    2,424,633    - 
                     
Total operating expenses   194,840    176,217    3,142,715    1,101,404 
Gain on sale of Gravitas   3,719,882    -    3,719,882    - 
Net income (loss) from discontinued operations   3,525,042    (176,217)   577,167    (1,101,404)

 

Gravitas Note

 

As consideration for the membership interests, Buyer and Gravitas, jointly and severally, issued to the Company the Gravitas Note, an unsecured promissory note in the original principal amount of $3,500,000 (see Note 2), and Buyer agreed to make the contingent milestone payments described below under “Milestone Payments.” The Gravitas Note bears interest at 15% per annum, which accrues as payment-in-kind interest and is capitalized and added to the outstanding principal balance at the end of each successive six-month period following issuance, and matures on July 17, 2029. The Gravitas Note may be prepaid at any time without premium or penalty and is subject to mandatory prepayment from at least 25% of the net proceeds of any equity, equity-linked or debt financing consummated by Buyer or Gravitas prior to maturity and, upon the consummation of a Pubco Transaction (as defined in the Gravitas Note), of the lesser of $1,000,000 and the outstanding balance. Upon an event of default, including a change of control of Buyer or Gravitas, the Gravitas Note becomes immediately due and payable and bears additional interest at 3.5% per annum. The Gravitas Note is neither guaranteed nor secured, and the Company may not transfer it without the consent of Buyer and Gravitas.

 

The Gravitas Note is measured at amortized cost and is presented as note receivable (related party) on the condensed consolidated balance sheets; the Company’s accounting policy for the Gravitas Note, including the evaluation of expected credit losses, is described in Note 2. At September 30, 2026, the carrying amount of the Gravitas Note was $3,606,997, consisting of principal of $3,500,000 and accrued payment-in-kind interest of $106,997, which is included in interest income in continuing operations for the three and nine months ended September 30, 2026. No payments had been received under the Gravitas Note as of September 30, 2026; see Note 11 for prepayments received in October 2026. Buyer and Gravitas are related parties of the Company (see Note 8). $1,125,000 of the Gravitas Note is presented within current assets, reflecting the prepayments received subsequent to the balance sheet date, and $2,481,997 is presented within non-current assets.

 

F-25

 

 

Milestone Payments

 

Under the Purchase Agreement, Buyer agreed to pay, or cause Gravitas to pay, the Milestone Payments of up to $3,000,000 in the aggregate upon the achievement of specified clinical development and regulatory approval milestones, consisting of up to $1,700,000 in respect of TH104 and up to $1,300,000 in respect of the products licensed from Intract Pharma Limited. Certain of the TH104 milestones are payable only if achieved by specified dates between the fourth quarter of 2027 and the third quarter of 2030. The Milestone Payments are contingent upon the achievement of future development and regulatory milestones by Buyer and Gravitas, which are outside the Company’s control. No amount has been recognized for the Milestone Payments in the condensed consolidated financial statements or in the gain on sale of Gravitas, and no amount will be recognized until the related milestones are achieved and the payments become due. No Milestone Payments had become due as of September 30, 2026. Earned but unpaid Milestone Payments are subject to offset against the Company’s indemnification obligations, as described below.

 

Gain on Sale

 

The Company derecognized the assets and liabilities of Gravitas at the closing date and recognized a gain on sale of $3,719,882 within net income (loss) from discontinued operations for the three and nine months ended September 30, 2026, equal to the $3,500,000 principal amount of the Gravitas Note plus $219,882 of net liabilities of Gravitas assumed by Buyer. The Milestone Payments were excluded from the consideration used to measure the gain.

 

Indemnification and Other Obligations under the Purchase Agreement

 

Under the Purchase Agreement, the Company agreed to indemnify Buyer and its affiliates, including Gravitas, for losses arising from any inaccuracy in or breach of the Company’s representations and warranties and any breach of its covenants. The representations and warranties generally survive for eighteen months following the closing, and the representations regarding organization, title to the purchased securities and authority survive for six years. Except in the case of fraud, the Company’s aggregate indemnification liability is limited to the aggregate purchase price actually paid to the Company, consisting of the principal amount of the Gravitas Note together with interest paid or payable thereon and any Milestone Payments paid or payable. Indemnifiable losses finally resolved in favor of Buyer are recoverable first by permanent offset against earned but unpaid Milestone Payments, then against accrued interest and outstanding principal under the Gravitas Note, and thereafter directly from the Company. Buyer agreed to indemnify the Company for losses arising from breaches of Buyer’s representations, warranties and covenants and from certain severance claims asserted by a former employee of Gravitas. Transfer taxes arising from the Gravitas Transaction are borne equally by the Company and Buyer. The Company also agreed that, for five years following the closing, it will hold in confidence non-public information relating to Gravitas and its business and will not solicit, induce or interfere with any customer, supplier or other business relation of Gravitas, and it agreed to provide litigation support and email cooperation to Buyer at Buyer’s expense. The Company has not recorded any liability in respect of its indemnification obligations under the Purchase Agreement as of September 30, 2026.

 

Note 11 – Subsequent Events

 

The Company evaluated subsequent events through the date these condensed consolidated financial statements were issued. On October 7, 2026, following the consummation of a Pubco Transaction (as defined in the Gravitas Note), Buyer prepaid $1,000,000 of the outstanding balance of the Gravitas Note, and on October 8, 2026, Buyer made a further mandatory prepayment of $125,000 from the proceeds of a financing, in each case as required under the terms of the Gravitas Note (see Note 10). The prepayments, totaling $1,125,000, reduced the outstanding balance of the Gravitas Note and will be reflected in the Company’s condensed consolidated financial statements for the quarter ending December 31, 2026. Except as described above, there were no material subsequent events that required recognition or additional disclosure in these condensed consolidated financial statements.

 

F-26

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited interim condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Annual Report”), as may be amended, supplemented, or superseded from time to time by other reports we file with the SEC. All amounts in this report are in U.S. dollars, unless otherwise noted.

 

Throughout this Quarterly Report on Form 10-Q, references to “we,” “our,” “us,” the “Company,” or “Canton Strategic Holdings,” refer to Canton Strategic Holdings, Inc., individually, or as the context requires, collectively with its subsidiary.

 

Overview

 

From 2022 through late 2025, we primarily operated as a biotechnology company developing therapeutic candidates in inflammatory and immunologic conditions. In November 2025, we undertook a strategic shift to prioritize a disciplined digital asset treasury management strategy and investment in the digital asset ecosystem, specifically the Canton Network. Our digital asset treasury strategy is centered on acquiring, holding and deploying Canton Coin (“CC”) and supporting the Canton Network through validator operations, application support and ecosystem participation.

 

In connection with this shift, in November 2025 we completed a private placement offering of common stock and pre-funded warrants for cash (the “Cash Offering”) and of pre-funded warrants for Canton Coin (the “Cryptocurrency Offering”), strengthening our liquidity and supporting our digital asset treasury strategy. Concurrently, we entered into an at-the-market sales agreement (the “2025 ATM Agreement”) under our shelf registration statement, which we amended and restated in March 2026 (the “March 2026 ATM Agreement”). In January 2026, we completed an underwritten offering of common stock and pre-funded warrants (the “January 2026 Offering”), further strengthening our capital position. These transactions are described in Note 4 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

On July 17, 2026, we completed the sale of Gravitas Life Sciences, Inc. (“Gravitas”), the subsidiary through which we conducted our biotechnology operations, and retained certain assets of Gravitas relating to bispecific antibodies development (the “Oncology Program”) through our wholly owned subsidiary, Tharimmune SPV1, LLC. The results of Gravitas are presented as discontinued operations for all periods presented, and our continuing operations consist of our digital asset treasury strategy and Canton Network operations. See “Recent Developments - Gravitas Transaction” below.

 

Recent Developments

 

Board Update

 

On July 13, 2026, we held our 2026 annual meeting of stockholders (the “Annual Meeting”). Sean Galvin, Pamela L. Carter, and Rishi Nangalia were elected as directors of the Board of Directors, effective July 13, 2026.

 

4

 

 

Gravitas Transaction

 

On July 16, 2026, Gravitas converted into a Delaware limited liability company, Gravitas Life Sciences, LLC, and we sold all of the issued and outstanding membership interests of Gravitas (the “Purchased Securities”) to Gravitas Collective Corp., a Delaware corporation (“Buyer”), pursuant to a Securities Purchase Agreement dated July 17, 2026 (the “Purchase Agreement”) (such sale, the “Gravitas Transaction”). Buyer is affiliated with Vincent LoPriore, Sireesh Appajosyula and Gary Stetz, former directors of the Company. The Gravitas Transaction was reviewed by a special committee of independent non-interested directors and, on July 15, 2026, was approved by the special committee and, upon its recommendation, by the full Board of Directors. See Note 10 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. The Gravitas Transaction was completed on July 17, 2026. As consideration for the Purchased Securities, Buyer and Gravitas issued to the Company an unsecured promissory note in the original principal amount of $3,500,000 (the “Gravitas Note”) and agreed to pay to the Company cash development and regulatory milestone payments of up to $3,000,000 in the aggregate (the “Milestone Payments”) in the event such payments become due and payable. The Gravitas Note bears interest at a rate of 15% per annum, payable in kind and compounding semi-annually, with accrued interest added to the outstanding principal balance, and matures on July 17, 2029, subject to optional prepayment and to mandatory prepayment from the net proceeds of future financings and upon a Pubco Transaction (as defined in the Gravitas Note). Prior to the closing, the Oncology Program was transferred to our wholly owned subsidiary, Tharimmune SPV1, LLC, and retained by the Company.

 

We recognized a gain on the sale of Gravitas of $3.7 million within net income from discontinued operations for the three and nine months ended September 30, 2026, equal to the $3.5 million principal amount of the Gravitas Note plus the net liabilities of Gravitas assumed by Buyer. No amount has been recognized for the contingent Milestone Payments. At September 30, 2026, the carrying amount of the Gravitas Note, including $0.1 million of accrued payment-in-kind interest, was $3.6 million and is presented as note receivable (related party) on our condensed consolidated balance sheets. No allowance for credit losses was recorded. In October 2026, Buyer prepaid $1.1 million of the Gravitas Note in accordance with its mandatory prepayment provisions. See Notes 2, 8, 10 and 11 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Components of Results of Operations

 

Revenue

 

During the three and nine months ended September 30, 2026, the Company recorded revenues for Canton Network validation rewards and for CC locking services.

 

Network validation rewards

 

The Company operates node infrastructure on the Canton Network in two capacities:

 

● Super Validator (“SV”): an institutional-grade operator that runs Byzantine fault-tolerant consensus infrastructure for the Global Synchronizer, participates in network governance, and helps maintain the shared ordering and settlement layer used by all network participants.

 

● Validator: an operator of a node used to participate in the network (directly or on behalf of application users), demonstrating uptime and processing transaction traffic.

 

The Canton Network’s native token, CC, is issued under a burn-and-mint equilibrium model rather than a fixed block-reward schedule:

 

● New CC is minted approximately every ten minutes (a “round”) and allocated among three participant classes - Super Validators, Validators, and application providers - based on protocol-defined formulas.

 

● CC supply follows a declining issuance curve designed to reward early contributors while trending toward long-term sustainability. CC issuance started high to bootstrap participation and app development, then halves periodically (with the next halving in the second quarter of 2029) to balance inflation and burn. The share of new CC issuances has shifted from favoring SVs to applications.

 

● Network usage fees are separately burned (removed from circulating supply), and the protocol targets a long-run equilibrium between coins minted and coins burned.

 

● Rewards are earned as mintable “coupons” that the validator’s software claims each round; unclaimed coupons expire and are not carried forward.

 

5

 

 

● Actual minting of SV rewards requires the node operator to meet specific deliverables as outlined in an approved Canton Improvement Proposal (“CIP”) to operate on the Canton Network. Upon initial approval, an SV’s reward weight is recorded after each round to a ghost (or “escrow”) node but actual CC minting to the SV’s wallet only occurs after their initially approved weight is unlocked (in whole or in part) via explicit approval of the Canton Foundation Accountability Committee who determines if deliverables required have been met. Upon Accountability Committee approval, the approved unlock portion begins minting to the SV wallet on a per-round basis. The approved weight portion of any accumulated rewards captured in the escrow node are subject to further review and calculation verification and a second committee approval vote, at which time a “one time mint” event occurs and a lump sum of CC is then minted to the SV wallet accordingly.

 

The Company was approved for SV weight of four (4) under CIP 102 in January 2026, and was approved for additional SV weight of eleven (11) under CIP 114 in April 2026. Active minting of 0.5 weight SV rewards began in May 2026 when the Company met the first of eight (8) deliverables under CIP 102. During the three months ended September 30, 2026, an additional 0.5 weight under CIP 102 and 5.5 weight under CIP 114 were released for active minting, increasing the Company’s active SV weight to 6.5. The amount reported in Network validation revenue for the three and nine months ended September 30, 2026 includes CC rewards from active daily minting of SV rewards at 0.5 weight through mid-July 2026 and at the increased weight thereafter, along with a one-time CC mint of approximately 5.1 million CC, recognized as revenue of approximately $0.6 million, associated with the accumulated released weight from the applicable approval dates through the unlock date in July 2026. As of September 30, 2026, in addition to the 6.5 active SV CC rewards minting, a weight of 8.5 is being recorded under CIP 102 and CIP 114 (3.0 and 5.5, respectively). Such weight is not currently eligible for active reward minting and will become eligible for release only upon satisfaction of the applicable milestone requirements and completion of the applicable Canton Network review and approval processes. Based on the currently applicable milestone schedules, and assuming the Company satisfies all applicable requirements, the Company expects the remaining weight to become eligible for release through the first quarter of 2028:

 

   Three Months Ended 
   2026   2027   2028 
   30-Sep   31-Dec (E)   31-Mar (E)   30-Jun (E)   30-Sep (E)   31-Dec (E)   31-Mar (E) 
CIP 102 (1)                            
Active weight (2)   0.5                         
Additional weight   0.5    0.5    0.5    0.5    0.5    0.5    0.5 
Total CIP 102 weight   1.0    1.5    2.0    2.5    3.0    3.5    4.0 
CIP 114 (3)                                   
Additional weight (2)   5.5    1.375    1.375    1.375    1.375    -    - 
Total CIP 114 weight   5.5    6.875    8.25    9.625    11    11    11 
Total SV weight   6.5    8.375    10.25    12.125    14.0    14.5    15.0 

 

(1) Under CIP 102, the Company may earn 0.5 SV weight for each quarterly milestone period, consisting of (i) 0.25 SV weight for publishing a quarterly Canton ecosystem research report addressing, among other matters, on-chain analytics, community developments, governance and tokenomics, planned technology updates and dashboard statistics, and (ii) 0.25 SV weight for conducting an open-to-the-public webinar of at least 45 minutes addressing substantially similar topics. The remaining 3.0 SV weight reflected above therefore represents six quarterly milestone periods.

 

(2) For the three and nine months ended September 30, 2026, the Company earned 13,230,413 CC and 14,484,092 CC in rewards associated with the active SV weight under CIP 102 and CIP 114, which were recognized as Network validation revenue of $1,503,238 and $1,694,464, respectively.

 

(3) Under CIP 114, the Company’s allocated SV weight is subject to quarterly review and a continuing requirement that the Company maintain CC holdings at or above the applicable CC Quantum established under the program. 50% of the applicable allocated weight became eligible for release following the first quarterly review which occurred during the three months ended September 30, 2026. Assuming that the requirement continues to be satisfied, one-fourth of the remaining 50% becomes eligible for release at each of the next four quarterly reviews.

 

6

 

 

CC Locking Services

 

CIP 105 requires SVs on the Canton Network to lock a specified amount of CC in order to maintain their minting weight (i.e., their proportional entitlement to network validator rewards). CIP 116 imposes an analogous locking requirement on Featured Applications (“Featured Apps”) in order for those applications to maintain their featured status and associated reward entitlements. Neither CIP requires that the locked CC be owned by the SV or Featured App itself - only that a qualifying amount of CC be identifiably locked and associated with that party’s wallet ID for the Canton Foundation’s compliance-tracking purposes.

 

This structure has given rise to a market for locking-as-a-service (“LAAS”): parties that hold CC (such as the Company) contract with SVs and Featured Apps to lock Company-owned CC on their behalf, in exchange for a fee, so that those counterparties can satisfy their CIP 105 / CIP 116 obligations without having to source and hold the requisite CC themselves.

 

For each LAAS customer, the Company places the agreed amount of CC into a separately identified wallet, held for the full term of the agreement within the Company’s qualified custodian. The Company retains legal and beneficial ownership of the CC at all times - the arrangement is not a transfer of the CC to the counterparty and does not constitute a loan of the underlying asset in a legal sense. Only the wallet ID (not custody, title, or control) is shared with the Canton Foundation, solely to allow the Foundation to verify the counterparty’s compliance with the applicable CIP locking provisions.

 

Because the CC is never transferred to the customer, the Company’s CC treasury holdings continue to be accounted for under the Company’s existing crypto asset accounting policy throughout the term of each LAAS arrangement, irrespective of the compensation structure of that arrangement. What the Company transfers to the customer is, in substance, the benefit of the CC being visibly and verifiably locked in the Company’s wallet - i.e., a stand-ready locking service - not the CC itself.

 

LAAS enables the Company to generate yield on its CC treasury asset and the majority of LAAS customers pay for the service in CC, which compounds the Company’s own treasury position. Through LAAS arrangements, the Company supports Canton Network ecosystem initiatives that are expected to drive application activity and network utilization, expand our counterparty relationships and our ability to influence the conditions which we believe support long-term CC value.

 

Derivatives – Option Contracts

 

During the quarter ended June 30, 2026, the Company began entering into CC-denominated option contracts through the sale of collateral-secured put options, as a part of its digital asset strategy. The Company records premiums earned and fair value remeasurement in Other revenue. During the three months ended September 30, 2026, the put option outstanding as of June 30, 2026 was exercised and settled through the purchase of CC at the strike price, and the Company had no outstanding CC option contracts as of September 30, 2026.

 

Research and Development Expenses

 

Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials, and manufacture drug supplies and materials as well as stock-based compensation for our research and development personnel. Research and development expenses are charged to operations as incurred. With the exception of costs related to the Oncology Program (see Note 10 to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q), all research and development expenses have been classified as discontinued operations.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of compensation and consulting related expenses, including stock-based compensation for our general and administrative personnel. General and administrative expenses also include professional fees and other corporate expenses, including legal fees relating to corporate matters; professional fees for accounting, auditing, tax, and consulting services; insurance costs; travel expenses and other operating costs that are not specifically attributable to research activities. General and administrative expenses also include expenses related to our Canton-centric digital asset treasury strategy.

 

7

 

 

We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support our digital asset treasury strategy. We also incur expenses associated with being a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, directors and officers insurance expenses, corporate governance expenses, investor relations activities and other administrative and professional services.

 

Interest Income

 

Interest income consists of interest income from funds held in our cash and cash equivalents accounts and, from July 17, 2026, payment-in-kind interest earned on the Gravitas Note.

 

Unrealized Loss from Digital Assets Holdings

 

The unrealized gain (loss) from digital assets holdings represents the change in fair value of our digital assets (CC) and any CC denominated receivables. We use a USD/CC reference price from a crypto market data provider for purposes of periodic fair value remeasurement.

 

Results of Continuing Operations

 

Three Months Ended September 30, 2026 Compared to the Three Months Ended September 30, 2025

 

   Three Months Ended September 30, 
   2026   2025   Change 
             
Consolidated Statements of Continuing Operations Data:               
Revenue               
Network validation revenue  $1,503,238   $-   $1,503,238 
Other revenue   1,547,994    -    1,547,994 
                
Total revenue   3,051,232    -    3,051,232 
                
Operating expenses:               
Research and development   -    101,586    (101,586)
General and administrative   2,710,641    1,815,775    894,866 
                
Total operating expenses   2,710,641    1,917,361    793,280 
                
Other income (expense):               
Interest expense   -    (9,648)   9,648 
Interest income   376,820    1,388    375,432 
Unrealized loss from digital assets holdings   (54,648,199)   -    (54,648,199)
                
Total other expense, net   (54,271,379)   (8,260)   (54,263,119)
                
Loss before income taxes  $(53,930,788)  $(1,925,621)  $(52,005,167)
                
Benefit for income taxes   15,327,449    -    15,327,449 
                
Net loss from continuing operations   (38,603,339)   (1,925,621)   (36,677,718)
                
Net income (loss) from discontinued operations   3,525,042    (176,217)   3,701,259 
                
Net loss  $(35,078,297)  $(2,101,838)  $(32,976,459)

 

8

 

 

Revenue

 

Revenues increased by $3.1 million for the three months ended September 30, 2026. Network validation revenue was $1.5 million, consisting of SV rewards earned with respect to our CIP 102 active weight and SV rewards with respect to the additional 0.5 CIP 102 weight and 5.5 CIP 114 weight released for active minting during the quarter, including approximately $0.6 million from a one-time mint of CC rewards in July 2026. Other revenue was $1.6 million, primarily earned under LAAS agreements, and included $0.1 million of net gains on CC option contracts. We did not generate any revenue for the same period in 2025 as we did not operate an SV or have LAAS activities.

 

Research and Development Expenses

 

Research and development expenses decreased by $0.1 million, or 100%, to $0 for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025. The Company has not incurred any research and development expenses related to the Oncology Program during the current period.

 

General and Administrative Expenses

 

General and administrative expenses increased by $0.9 million, or 49%, to $2.7 million for the three months ended September 30, 2026 from $1.8 million for the three months ended September 30, 2025. The change in general and administrative expenses was primarily due to increases of $0.6 million in compensation and benefits expenses, $0.3 million in insurance expense, $0.2 million in information technology and digital asset related expenses, and $0.2 million in marketing and business development expenses, partially offset by a $0.4 million decrease in stock-based compensation expense.

 

Interest Expense

 

Interest expense decreased by $0.01 million, or 100%, to $0 for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025. The interest expense incurred in 2025 was primarily related to a director and officer insurance premium financing liability as well as a note payable. We have paid such obligations in full as of December 31, 2025 and did not incur any interest expense for the three months ended September 30, 2026.

 

Interest Income

 

Interest income increased by approximately $0.4 million, to $0.4 million for the three months ended September 30, 2026 from less than $0.01 million for the three months ended September 30, 2025. The increase in interest income was due to the increase in investible cash and equivalents and $0.1 million of payment-in-kind interest earned on the Gravitas Note following the closing of the Gravitas Transaction on July 17, 2026.

 

Unrealized Loss from Digital Assets Holdings

 

We recorded an unrealized loss from digital assets holdings of $54.7 million for the three months ended September 30, 2026. We did not have any loss (or gain) from digital asset holdings for the three months ended September 30, 2025. We did not own digital assets prior to the Cryptocurrency Offering in November 2025. The current period unrealized loss is a result of the reference price of CC as of September 30, 2026 being less than the reference price of CC as of June 30, 2026. See Note 3 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information about our digital assets holdings.

 

9

 

 

Benefit for Income Taxes

 

We recorded a benefit for income taxes of $15.3 million for the three months ended September 30, 2026, representing an effective tax rate of 28.4%, compared to no provision or benefit for income taxes for the three months ended September 30, 2025.

 

Discontinued Operations

 

Net income from discontinued operations was $3.5 million for the three months ended September 30, 2026, consisting of the $3.7 million gain on the sale of Gravitas partially offset by $0.2 million of operating expenses of Gravitas through the July 17, 2026 closing, compared to a net loss from discontinued operations of $0.2 million for the three months ended September 30, 2025. See Note 10 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Nine Months Ended September 30, 2026 Compared to the Nine Months Ended September 30, 2025

 

   Nine Months Ended September 30, 
   2026   2025   Change 
             
Consolidated Statements of Continuing Operations Data:               
Revenue               
Network validation revenue  $1,694,464   $-   $1,694,464 
Other revenue   2,852,627    -    2,852,627 
                
Total revenue   4,547,091    -    4,547,091 
                
Operating expenses:               
Research and development   -    316,673    (316,673)
General and administrative   40,629,835    5,073,330    35,556,505 
                
Total operating expenses   40,629,835    5,390,003    35,239,832 
                
Other income (expense):               
Interest expense   -    (24,280)   24,280 
Interest income   1,006,846    16,992    989,854 
Unrealized loss from digital assets holdings   (93,397,453)   -    (93,397,453)
                
Total other expense, net   (92,390,607)   (7,288)   (92,383,319)
                
Loss before income taxes  $(128,473,351)  $(5,397,291)  $(123,076,060)
                
Benefit for income taxes   26,219,864    -    26,219,864 
                
Net loss from continuing operations   (102,253,487)   (5,397,291)   (96,856,196)
                
Net income (loss) from discontinued operations   577,167    (1,101,404)   1,678,571 
                
Net loss  $(101,676,320)  $(6,498,695)  $(95,177,625)

 

10

 

 

Revenue

 

Revenues increased by $4.6 million for the nine months ended September 30, 2026. Network validation revenue was $1.7 million, consisting of SV rewards commencing in May 2026 with respect to our CIP 102 0.5 weight unlock and SV rewards with respect to the additional 0.5 CIP 102 weight and 5.5 CIP 114 weight released for active minting during the third quarter of 2026, including approximately $0.6 million from a one-time mint of CC rewards in July 2026. Other revenue was $2.9 million, primarily earned under LAAS agreements commencing in April 2026, and included $0.1 million of net gains on CC option contracts. We did not generate any revenue for the same period in 2025 as we did not operate an SV or have LAAS activities.

 

Research and Development Expenses

 

Research and development expenses decreased by $0.3 million, or 100%, to $0 for the nine months ended September 30, 2026 as compared to the nine months ended September 30, 2025. The Company has not incurred any research and development expenses related to the Oncology Program during the current period.

 

General and Administrative Expenses

 

General and administrative expenses increased by $35.6 million, or 701%, to $40.6 million for the nine months ended September 30, 2026 from $5.1 million for the nine months ended September 30, 2025. The change in general and administrative expenses was primarily due to increases of $31.5 million in stock-based compensation expense (see Note 5 to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q). The remaining increase of approximately $4.1 million was primarily attributable to increases of $2.2 million in compensation and benefits, $0.8 million in insurance expense, $0.5 million in marketing and business development expense, $0.4 million in digital asset related costs, and $0.2 million in legal and professional expenses.

 

Interest Expense

 

Interest expense decreased by $0.02 million, or 100%, to $0 for the nine months ended September 30, 2026 as compared to the nine months ended September 30, 2025. The interest expense incurred in 2025 was primarily related to a director and officer insurance premium financing liability as well as a note payable. We have paid such obligations in full as of December 31, 2025 and did not incur any interest expense for the nine months ended September 30, 2026.

 

Interest Income

 

Interest income increased by approximately $1.0 million, to $1.0 million for the nine months ended September 30, 2026 from $0.02 million for the nine months ended September 30, 2025. The increase in interest income was due to the increase in investible cash and equivalents and $0.1 million of payment-in-kind interest earned on the Gravitas Note following the closing of the Gravitas Transaction on July 17, 2026.

 

Unrealized Loss from Digital Assets Holdings

 

We recorded an unrealized loss from digital assets holdings of $93.4 million for the nine months ended September 30, 2026. We did not have any loss (or gain) from digital asset holdings for the nine months ended September 30, 2025. We did not own digital assets prior to the Cryptocurrency Offering in November 2025. The unrealized loss for the nine months ended September 30, 2026 is a result of the reference price of CC as of September 30, 2026 being less than the weighted average cost of our CC holdings. See Note 3 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information about our digital assets holdings.

 

Benefit for Income Taxes

 

We recorded a benefit for income taxes of $26.2 million for the nine months ended September 30, 2026, representing an effective tax rate of 20.4%, compared to no provision or benefit for income taxes for the nine months ended September 30, 2025.

 

11

 

 

Discontinued Operations

 

Net income from discontinued operations was $0.6 million for the nine months ended September 30, 2026, consisting of the $3.7 million gain on the sale of Gravitas partially offset by $3.1 million of operating expenses of Gravitas through the July 17, 2026 closing, compared to a net loss from discontinued operations of $1.1 million for the nine months ended September 30, 2025. See Note 10 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Known Trends, Events and Uncertainties

 

Business operations. Following our November 2025 and January 2026 financings, we have focused on expanding our digital asset treasury strategy and Canton Network operations. We continue to grow our CC holdings through operation as an SV on the Canton Network and through LAAS, which we began offering to other Canton Network participants in April 2026. Our ability to execute this strategy depends on continued capital availability and favorable market conditions for CC.

 

Super Validator weight releases. Our network validation revenue depends on our active SV weight, which increased during the third quarter of 2026 as additional allocated weight was released for active minting. The release of the remaining allocated weight through the first quarter of 2028 is subject to our satisfaction of the applicable milestone requirements and Canton Network approval. Under CIP 114, our allocated weight is also subject to quarterly review and a continuing requirement that we maintain CC holdings at or above the applicable CC Quantum established under CIP 114.

 

Canton Coin price volatility. Our financial results and the carrying value of our digital asset holdings are significantly affected by the market price of CC, which has historically been volatile. Fluctuations in the price of CC could materially affect our financial position, results of operations and cash flows, and our ability to raise additional capital on acceptable terms.

 

Capital markets and liquidity. We believe our November 2025 and January 2026 financings, shelf registration and the March 2026 ATM Agreement provide flexibility to access equity capital opportunistically to support working capital and selective investments aligned with our strategy. Adverse market conditions or unfavorable industry sentiment could constrain our ability to raise capital on acceptable terms.

 

Regulatory environment. Evolving U.S. and foreign regulations related to digital assets, blockchain networks, staking and validation services, and custody of crypto assets may impose new compliance obligations or restrictions on our business.

 

Gravitas Transaction. Following the sale of Gravitas on July 17, 2026, we no longer fund the operations of the legacy clinical-stage biotechnology business other than the retained Oncology Program. The Gravitas Note is unsecured, and our ability to collect it depends on the financial condition of Buyer and Gravitas and on their completion of future financings or a Pubco Transaction that would trigger mandatory prepayment; we estimate expected credit losses on the Gravitas Note each reporting period. On October 7 and 8, 2026, Buyer made prepayments in aggregate of $1,125,000 pursuant to the Gravitas Note. See Note 11 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. We have not recognized any amount for the Milestone Payments of up to $3.0 million, which are contingent on future clinical development and regulatory events outside our control, and we do not rely on the Gravitas Note or the Milestone Payments as a source of near-term liquidity. Under the Purchase Agreement we agreed to indemnify Buyer for losses arising from breaches of our representations, warranties and covenants, generally for eighteen months following the closing; except in the case of fraud, our aggregate liability is limited to the aggregate purchase price actually paid to us, and indemnifiable losses are recoverable first by offset against earned but unpaid Milestone Payments, then against the Gravitas Note, and thereafter directly from us. We have not recorded any liability for these indemnification obligations. See Notes 2, 8 and 10 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Liquidity and Capital Resources

 

In November 2025, we received net proceeds of approximately $537.1 million through the Cash Offering and the Cryptocurrency Offering, of which approximately $446.2 million was received in CC rather than cash, and on January 21, 2026 we raised net proceeds of approximately $52.7 million in the January 2026 Offering and have raised net proceeds of approximately $40.1 million during the nine months ended September 30, 2026 pursuant to the 2025 ATM Agreement and the March 2026 ATM Agreement. No shares were repurchased under our share repurchase program approved in June 2026 during the nine months ended September 30, 2026. We believe we have sufficient liquidity to fund anticipated cash requirements for operations and working capital purposes for at least the next twelve months from the date of this Quarterly Report on Form 10-Q.

 

12

 

 

As of September 30, 2026, we had cash and cash equivalents of $26.9 million and digital assets with a fair value of $482.1 million. Our primary sources of liquidity are our cash and cash equivalents, our digital asset holdings, which we may sell or otherwise deploy subject to market conditions, and our ability to access the equity capital markets, including approximately 285.9 million of the $300.0 million available under the March 2026 ATM Agreement. Our principal uses of cash are the operating costs of our business and purchases of CC. We may also use cash to repurchase shares under our share repurchase program approved in June 2026 (the “2026 Share Repurchase Program”), which does not obligate us to repurchase any shares. We do not currently have any material cash requirements from known contractual obligations other than ordinary course obligations reflected on our condensed consolidated balance sheet.

 

Cash Flow Activities for the Nine Months Ended September 30, 2026 and 2025

 

The following table sets forth a summary of our cash flows for the periods presented.

 

   Nine Months Ended September 30, 
   2026   2025 
Net cash used in operating activities – continuing operations  $(7,918,661)  $(4,490,573)
Net cash used in operating activities – discontinued operations   (4,456,077)   (1,196,127)
Net cash used in investing activities – continuing operations   (69,842,182)   - 
Net cash provided by financing activities – continuing operations   92,101,608    9,737,679 
Net increase (decrease) in cash  $9,884,688   $4,050,979 

 

Cash Flows from Operating Activities

 

Cash used in operating activities - continuing operations for the nine months ended September 30, 2026 was $7.9 million, which consisted of net loss from continuing operations of $102.3 million, adjusted for non-cash stock based compensation of approximately $32.3 million, unrealized loss from digital asset holdings of approximately $93.4 million, the deferred tax benefit of $26.2 million, non-cash revenue adjustment of $4.5 million for network validation and related services, payment-in-kind interest on the Gravitas Note of $0.1 million, and a net increase in operating assets, net of liabilities, of approximately $0.6 million. Because substantially all of our revenue is received in CC and retained as digital assets, our operating cash flow primarily reflects the cash operating costs of our business, partially offset by interest income earned on our cash and cash equivalents of approximately $0.9 million. The net change in operating assets and liabilities reflected a decrease in accounts payable of $0.6 million and an increase in prepaid expenses of $0.4 million, primarily annual insurance premiums paid in January 2026, partially offset by an increase in accrued expenses of $0.4 million, primarily accrued compensation. Cash used in operating activities - discontinued operations was $4.5 million for the nine months ended September 30, 2026.

 

Cash used in operating activities - continuing operations for the nine months ended September 30, 2025 was $4.5 million which consisted of net loss from continuing operations of $5.4 million, adjusted for non-cash stock based compensation of $0.9 million and the write-off of deferred offering costs of $0.1 million. Cash used in operating activities - discontinued operations was $1.2 million for the nine months ended September 30, 2025.

 

Cash Flows from Investing Activities

 

Cash used in investing activities for the nine months ended September 30, 2026 was $69.9 million, representing the purchase of digital assets. Purchases of CC during the three and nine months ended September 30, 2026 included $6.1 million and $55.3 million, respectively, purchased in OTC transactions from a cryptocurrency liquidity provider under the control of a shareholder who beneficially owns more than 5% of our outstanding common stock (see Note 8). Purchases of digital assets include $1.0 million of cash collateral that we posted in June 2026 in connection with a written CC put option and that was applied to the purchase price of 6,250,000 CC upon exercise of the option in July 2026; no collateral was outstanding at September 30, 2026. The sale of Gravitas in July 2026 did not generate cash proceeds; the receipt of the Gravitas Note was a non-cash investing activity. There were no cash flows from investing activities during the nine months ended September 30, 2025.

 

13

 

 

Cash Flows from Financing Activities

 

Cash provided by financing activities for the nine months ended September 30, 2026 was $92.1 million. The net increase in financing activities was due to proceeds from the January 2026 Offering of $54.9 million, proceeds from the 2025 ATM Agreement and March 2026 ATM Agreement offerings of $40.7 million, and proceeds from the exercise of warrants of $0.2 million. These increases were offset by payments of issuance costs of $3.6 million.

 

Cash provided by financing activities for the nine months ended September 30, 2025 was $9.7 million. The net increase in financing activities was due to proceeds from registered direct public offerings of $7.1 million, proceeds from private investment in public equity offerings of $3.7 million, proceeds from at-the-market offerings of $0.3 million and proceeds from insurance premium financing liability of $0.3 million, offset by payments of issuance costs of $1.2 million, payments of the insurance premium financing liability of $0.3 million and repayments of the note payable of $0.2 million.

 

Critical Accounting Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. We consider the following areas to be our critical accounting estimates: fair value of digital assets, measurement of revenue received in CC, stock-based compensation, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations. Although management believes the estimates that have been used are reasonable, actual results could vary from the estimates that were used.

 

Our critical accounting estimates are described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Use of Estimates” in our 2025 Annual Report. There have been no material changes to those estimates during the nine months ended September 30, 2026, other than as described below.

 

Fair value of digital assets. Our digital assets, consisting of CC, are measured at fair value each reporting period based on quoted prices in our principal market, and changes in fair value are recognized in net loss. As of September 30, 2026, the fair value of our digital assets was $482.1 million, and we recognized an unrealized loss of $93.4 million for the nine months ended September 30, 2026. The determination of our principal market requires judgment, and the carrying amount of our digital assets is directly sensitive to the CC reference price; a 5% change in the CC reference price at September 30, 2026 would have changed the carrying amount of our digital assets and our net loss by approximately $24.1 million.

 

Revenue received in CC. Network validation revenue and LAAS revenue denominated in CC are measured at the fair value of the CC on the date we obtain control of it, using the daily CC/USD reference rate, and revenue share arrangements are measured once at month-end in the finalized amount. The amount of revenue recognized therefore depends on both the quantity of CC earned and the CC reference price on the measurement date.

 

Our significant accounting policies are described in Note 2 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

Recently Issued and Adopted Accounting Standards

 

See Note 2 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

14

 

 

JOBS Act

 

On April 5, 2012, the Jumpstart Our Business Startups Act (the “JOBS Act”) was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards.

 

Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including, without limitation, (i) providing an auditor’s attestation report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, and (ii) complying with the requirement adopted by the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor’s report on financial statements. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our IPO; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

Our principal executive officer and principal financial officer evaluated the effectiveness of our “disclosure controls and procedures” as of September 30, 2026, the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is accumulated and communicated to a company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on Effectiveness of Controls and Procedures

 

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

15

 

 

PART II — OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

 

ITEM 1A. RISK FACTORS.

 

Risk factors that affect our business and financial results are discussed in Part I, Item 1A “Risk Factors,” in the 2025 Annual Report. Except as described below, there have been no material changes in our risk factors from those previously disclosed in the 2025 Annual Report. You should carefully consider the risks described in the 2025 Annual Report which could materially affect our business, financial condition or future results. The risks described in the 2025 Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. If any of the risks actually occur, our business, financial condition, and/or results of operations could be negatively affected.

 

On July 17, 2026, we completed the sale of Gravitas. As a result of the completion of this transaction, the risks described under “Risks Related to Our Therapeutic Candidates Developments” in the 2025 Annual Report are no longer applicable.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

There were no sales of unregistered equity securities during the three months ended September 30, 2026.

 

Issuer Purchases of Equity Securities

 

On June 11, 2026, the Company’s Board of Directors approved the 2026 Share Repurchase Program providing for the repurchase of up to $50 million of the Company’s outstanding shares of common stock. Under the 2026 Share Repurchase Program, the Company is authorized to repurchase shares through open market purchases, privately negotiated transactions or otherwise in accordance with applicable federal securities laws, including through trading plans intended to comply with Rule 10b-18 under the Exchange Act. In connection with the program, on June 12, 2026 the Company entered into a Rule 10b-18 repurchase agreement with Virtu Americas LLC, as broker. The 2026 Share Repurchase Program does not obligate the Company to repurchase any shares of common stock. We have not repurchased any shares of our common stock under the 2026 Share Repurchase Program during the three months ended September 30, 2026.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable

 

ITEM 5. OTHER INFORMATION.

 

During the fiscal quarter ended September 30, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

 

16

 

 

ITEM 6. EXHIBITS.

 

Exhibit No.   Description
3.1   Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 18, 2026)
     
4.1   Form of Pre-Funded Warrant (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 22, 2026)
     
10.1   Securities Purchase Agreement, dated as of July 17, 2026, by and between Gravitas Collective Corp. and Canton Strategic Holdings, Inc. (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 23, 2026)
     
10.2   Unsecured Promissory Note (Seller Note), dated July 17, 2026, issued by Gravitas Collective Corp. and Gravitas Life Sciences, LLC to Canton Strategic Holdings, Inc. (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on July 23, 2026)
     
10.3   Bill of Sale, Assignment and Assumption Agreement, dated July 17, 2026, by and between Gravitas Life Sciences, LLC and Tharimmune SPV1, LLC. (Incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on July 23, 2026)
     
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   Inline XBRL Instance Document
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104*   Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 is formatted in Inline XBRL included in the Exhibit 101 Inline XBRL Document Set

 

* Filed herewith.
** Furnished herewith.
+ Indicates a management contract or any compensatory plan, contract or arrangement.

 

17

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CANTON STRATEGIC HOLDINGS, INC.
     
Date: November 16, 2026 By: /s/ Mark Wendland
    Mark Wendland
    Chief Executive Officer
    (Principal Executive Officer)
     
Date: November 16, 2026 By: /s/ Jacob Asbury
    Jacob Asbury
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

18

 

Keep reading